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It is recognised that mood disorder diagnostic categories are simplifications with 
limited validity, and while dimensional measures may be more valid than categories, 
their utility is uncertain. It has been argued that the criteria for bipolar disorder (BD) 
are too narrow, and that a ‘bipolar spectrum’ should be recognised. The validity and 
utility of a dimensional measure of mania, the Mood Disorder Questionnaire (MDQ), 
was investigated in a cohort (n = 68) of young adults being treated for an episode of 
major depressive disorder (MDD). MDQ score was higher in men and correlated 
positively with number of depressive episodes, personality measures, and negatively 
with reaction time. In those on antidepressants at three month follow up (n = 36), 
MDQ correlated moderately with restlessness (r = .39, p = .01) and suicidal thoughts 
(r = .34, p = .02). A genetic study of MDD, BD and categorically defined bipolar 
spectrum disorder (BSD) found an association with a single nucleotide 
polymorphism (rs1202874) in GPR50, on Xq28. When BD and BSD groups were 
combined, the association strengthened (p = .0014; OR 1.97, 95% CI 1.26-3.06). The 
MDQ was investigated in a sample (n=2942), from the population-based Generation 
Scotland biobank. The MDQ showed high internal reliability, and in a subset with 
MDD (n=620), a three component structure. MDQ was higher in men, and in those 
with recurrent depression, and correlated negatively with age of onset (r = -.191, p = 
2 x 10-6). A trimodal distribution of age-of-onset was observed in those with chronic 
or highly recurrent MDD. Controlling for age, gender and current distress, MDQ 
correlated negatively with general intelligence (r = -.100, p = 1 x 10-8) in controls. 
Overall there was reasonable evidence that the MDQ had antecedent, concurrent and 
predictive validity. There was less evidence to support the reliability or validity of 
BSD. The findings suggested that in those with MDD (particularly with risk factors 
such as male gender, early age of onset and recurrence) the MDQ may be useful to 
(1) identify those who may require more intensive monitoring and (2) inform 
treatment decisions. Thirdly, classifying mood disorders on the basis of prior course, 





This thesis is my work, except where stated. No part has been submitted for any 




Donald James MacIntyre 
 
25th April 2012 
 
3 
Chapter 1: Introduction 
The Scope of Mood Disorders 
 
Mood disorders are an international public health problem (Moussavi et al, 2007). 
The World Health Organisation (WHO) Global Burden of Disease study created a 
league table of 107 major causes of disability and early mortality worldwide. 
Unipolar depression came fourth (Murray & Lopez, 1997), above heart disease and 
stroke. Bipolar disorder was ranked (at number 22) above diabetes, asthma and 
schizophrenia. 
 
Epidemiological studies estimate that more than 1 in 6 individuals are afflicted by 
mood disorders at some point in their lives (Kessler et al, 1994, 2005) but current 
treatments are suboptimal for many patients: WHO studies found that about half of 
treated primary care attenders with depression are still depressed at the end of a year 
(Goldberg et al, 1998; Üstün & Kessler, 2002); a recent Dutch study showed that 
only were 43% of patients remitted at 6 months and did not suffer a recurrence over 
the next 3 years, while 17% remained chronically depressed (Stegenga et al, 2010). 
 
Mood disorders usually have their onset during working age (Jacobi et al, 2004), and 
tend to run a recurrent or chronic course (Piccinelli & Wilkinson, 1994; Kessler et al, 
1997; Simpson et al, 1997; Spijker et al, 2002; Perlis et al, 2006b; Eaton et al, 2008; 
Kessing, 2008; Rhebergen et al, 2009) with commensurate economic impact: In the 
UK, recent evaluations suggest that annual direct costs of depression may be as high 
as £1.7bn, while indirect annual costs of unipolar disorder was estimated to be 
£7.5bn and bipolar disorder £5.2bn. (Thomas & Morris, 2003; McCrone et al, 2008).  
 
A key difficulty in the clinical management of mood disorders is accurate diagnosis 
(NICE, 2010, pp. 23–24). The evidence that many patients currently diagnosed as 
‘unipolar’ will go on to suffer from mania (Akiskal, 1983; Goldberg et al, 2001a), 
and the longstanding recognition that our diagnostic concepts have poor validity 
 
4 
(Kendell, 1976; Farmer & McGuffin, 1989; Cole et al, 2008) have led to efforts to 
refine them. Proposals to recognise a dimensional spectrum of mood disorder 
(Akiskal, 1983; Ghaemi et al, 2008) may be more valid than current categories, but 
would increase the proportion of patients receiving a bipolar diagnosis (Smith et al, 
2011) and are the subject of heated debate (Baldessarini, 2000; Spence, 2011). 
 
A Brief Review of the Development of Mood Disorder 
Classification 
 
Approaches to classification of mental disorders have evolved many times since the 
first surviving descriptions, which were categorical in nature. Early accounts from 
the school of Hippocrates of Cos (ca. 460-380 BC) describe three distinct and 
mutually exclusive categories: phrenitis (which corresponds roughly to our 
conception of delirium), and two mood disorders: mania and melancholia, which 
were seen as separate and distinct ailments, with remorselessly deteriorating courses 
(Jackson, 1986). 
 
This distinction of separateness was challenged five centuries later, when Aretaeus 
the Cappadocian ('The Clinician of Mania', ca. 100AD) asserted: “Melancholia is the 
beginning part of mania … The development of a mania is really a worsening of the 
disease (melancholia) rather than a change into another disease.” (Angst & Marneros, 
2001). Although other writers acknowledged a close relationship between 
melancholia and mania, the orthodox view (that these conditions were distinct, 
separate and remorselessly deteriorating in course) predominated over much of the 
next two millennia. 
 
In 1759, the physician Anders Piquer published a monograph about his most famous 
patient: King Ferdinand VI of Spain, who was afflicted by “melancholic-manic 
affect”. Piquer believed that melancholia and mania were “one and the same illness” 
(Goodwin & Jamison, 2007, p. 5). In France an explicitly unitary conception of 
manic-depressive illness was asserted by Falret (who emphasised the cyclical nature 
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of mood disorders when he described ‘la folie circulaire’) and, simultaneously in 
1854, by Baillarger who described ‘la folie à double forme’. Hypomania was first 
defined by Mendel in 1881, and the following year, Kahlbaum recognised an 
attenuated form of alternating mood disorder that today we might classify as 
cyclothymia (Jackson, 1986). 
 
Kraepelin & Bleuler 
 
Emil Kraepelin (1856 – 1926) finally put the classification of mental illness onto a 
scientific footing when he began systematically collecting and analysing clinical data 
on hundreds of his patients. He revised his ideas over his lifetime, but by the eighth 
edition of his Textbook of Psychiatry (published in 1913) he conceived “manic-
depressive insanity” as a single disease entity encompassing all mood disorders, but 
separate from dementia praecox (schizophrenia), and distinguished by its recurrent 
course, family history, and its more benign prognosis. His concept of manic-
depressive insanity, a diagnosis which he applied to patients who had never 
experienced manic episodes (Kraepelin, 1921, p. 187) also included “slight 
colourings of mood” that “pass over without sharp boundary into the domain of 
personal disposition” (Kraepelin, 1921, p. 1), an observation that presaged 
contemporary spectrum concepts (Angst, 2002). 
  
Bleuler’s view that “Except in the rare extreme cases we now no longer have to ask, 
is it manic-depressive or schizophrenia? but to what extent manic-depressive and to 
what extent schizophrenia?”, placed “affective” illness (as he termed it) and 
schizophrenia on a spectrum of disorder, without a point of rarity, determined by the 
number of schizophrenic features (Bleuler, 1924, p. 175). This essentially unitary 
view of mood disorder and psychosis remains controversial (Craddock & Owen, 




The Unipolar/Bipolar distinction 
 
In 1959 Leonhard proposed that those with recurrent mood disorder be divided into 
two groups: with bipolar (alternating mania and depression) or monopolar (recurrent 
mania or recurrent depression) courses (Leonhard, 1959). Angst and Perris in 
independent family studies (Angst, 1966; Perris, 1966) supported this unipolar-
bipolar distinction. However, the observation that relatives of patients with unipolar 
mania tend to suffer from both depression and mania, argued for the inclusion of 
unipolar mania in the ‘bipolar’ category (Abrams & Taylor, 1974; Pfohl et al, 1982) - 
and so it was the presence or absence of mania which became the key feature 
incorporated into DSM-III (Spitzer, 1981) and, later, DSM-IV and ICD-10. 
With this change in emphasis, the hitherto key feature of recurrence was discarded, 
significantly lowering the diagnostic threshold, particularly for unipolar disorder. A 
further result was that subsequent studies of ‘bipolar’ illness tended to focus only on 
those patients who had been hospitalised for mania, excluding those with more subtle 
manic symptoms and systematically (mis)classifying them as ‘unipolar’ 
(Zimmermann et al, 2009). 
 
The situation was partially redressed by the proposal, supported by family history 
evidence, to designate patients with depression (sufficient to require hospitalisation) 
and troublesome hypomania not requiring admission, as ‘bipolar II’ (Dunner et al, 
1976). Subsequent studies broadened the depressive criterion, dropping the need for 
admission, further expanding the concept of bipolar disorder (Baldessarini, 2000). 
 
Current Concepts of Mood (Affective) Disorder 
Diagnostic categories 
 
These classifications are detailed in ICD-10 (WHO, 1992) and DSM-IV-TR 
(American Psychiatric Association, 2000). The list of DSM-IV-TR mood disorders 
captures the difficulty of imposing a categorical system on a patient population in 
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whom proportions of symptoms vary, in a continuous fashion. See Table 1. 
 
Major Depressive Disorder 
Bipolar I Disorder (includes unipolar mania) 
Bipolar II Disorder 
Cyclothymic Disorder 
Dysthymic Disorder 
Bipolar Not Otherwise Specified (NOS) 
Mood disorder NOS 
Depression NOS 
   Table 1 DSM-IV-TR Mood Disorders 
 
Not only in the first category (in which patients can show modest manic symptoms), 
but also in the remaining seven categories, a mixture of manic and depressive 
symptoms may be present. It should be noted that five of the eight (italics) are 
residual ‘catch all’ NOS or ‘sub-threshold’ categories (dysthymia and cyclothymia). 
Attempts to reduce the proportion of patients in residual categories by creating new 
categories such as bipolar III, IV, V & VI (Klerman, 1981; Akiskal & Pinto, 1999) 
have not been enthusiastically adopted. A further indication of the poor validity of 
categorical approaches is that, in both clinical practice and in population samples, 
individuals usually fulfil criteria for more than one putatively distinct disorder 
(Kendell, 1975), or sometimes none (Welner et al, 1973). Attempts to validate mood 
disorder diagnoses rest on external validating criteria (Akiskal, 1980). 
 
Validity: External Criteria 
 
As Kendell stated, “validity is concerned with external correlates of class 
membership – the more important correlates a class has over its defining 
characteristics, the less likely its validity is to be questioned” (Kendell, 1989). 
Several strategies for establishing the validity of a clinical syndrome were outlined in 
a classic paper (see Table 2), initially applied to schizophrenia, in which family 
history and follow-up studies were used to make a distinction between ‘good’ and 




1. Identification and description of the syndrome, either by ‘clinical intuition' or by 
cluster analysis. 
2. Demonstration of boundaries or "points of rarity' between related syndromes by 
discriminant function analysis, latent class analysis, etc. 
3. Follow-up studies establishing a distinctive course or outcome. 
4. Therapeutic trials establishing a distinctive treatment response. 
5. Family studies establishing that the syndrome ‘breeds true’. 
6. Association with some more fundamental abnormality - histological, psychological, 
biochemical or molecular. 
Table 2 Strategies for establishing the validity of a clinical syndrome, after Robins & 
Guze, 1970. 
 
The features of ‘good prognosis schizophrenia’ in this study included depressive 
symptoms, guilt, thoughts of death and a strong family history of mood disorder, so 
arguably these patients may have been more appropriately diagnosed with a mood 
disorder. Other than follow up and family studies, methods for establishing validity 
include examining biological markers or ‘endophenotypes’ (Gottesman & Gould, 
2003), pharmacological response, and demonstration of points or zones of rarity. 
Validators may be considered as either antecedent, concurrent or predictive. 
Predictive validity is associated with clinical utility. 
 
Point of Rarity 
 
If categories are valid, it should be possible to demonstrate natural boundaries; zones 
or “points of rarity” between illness and normality, and between categories (Sneath, 





Figure 1 Hypothetical distribution of test scores in two related conditions; Mitchell,  
2010. 
 
However, symptoms of common mental disorders are continuously distributed in the 
consulting population (Goldberg, 2000; Thompson et al, 2001; Benazzi, 2003; 
Cassano et al, 2004; Mitchell, 2010), as is disability (Broadhead et al, 1990; Judd et 
al, 1996; Hermens et al, 2004; Backenstrass et al, 2006; Ayuso-Mateos et al, 2010), 
and no “point of rarity” allows mood disorders to be divided from ‘normality’. 
Nevertheless, present diagnostic systems are based on a check-list approach, and 
make arbitrary distinctions about threshold for ‘caseness’ based on criteria such as: 
number of symptoms (for example 5, or more, out of 9 depressive symptoms) 
(Kendler & Gardner, 1998); duration (for example at least 4 days duration of for 
hypomania) (Angst, 1998; Judd et al, 2003a) or level of impairment (again, for 






Predicting and altering the future is one of the primary functions of medicine, and a 
more or less distinctive course is inherent in the concept of a syndrome. However, to 
prove a qualitative rather than a quantitative difference, it is necessary to demonstrate 
that the relationship between outcome and symptomatology is non-linear (Kendell, 
1989). See Figure 2 
 
Figure 2 Relationship between symptomatology and outcome when symptomatology 
is converted to a linear variable 
 
X axis: discriminant function or other linear variable expressing variation in 
symptomatology; Y-axis: outcome score. A, Linear relationship; B, Non-linear 




The recognition that psychiatric syndromes represent heterogeneous groups of 
conditions (of limited utility for genetic dissection), and the hope that more 
intermediate or fundamental deficits might have simpler, perhaps Mendelian, genetic 
aetiology, led to the proposal to define phenotypes for genetic analysis by features 
not visible to the naked eye: so-called ‘endophenotypes’ (Gottesman & Shields, 
1973; Gottesman & Gould, 2003), also termed “biological markers”, “subclinical 
traits” and “intermediate phenotypes”. Endophenotypes may prove useful for 
clarifying classification systems and, it is hoped, ultimately for aiding diagnosis 





1. It is associated with illness in the population. 
2. It is heritable. 
3. It is primarily state-independent (manifests in an individual whether or not illness 
is active). 
4. Within families, it co-segregates with illness. 
5. It is found in non-affected family members at a higher rate than in the general 
population. 
Table 3 Characteristics of an Endophenotype; after Gottesman & Shields, 2003 
 
Personality features (such as neuroticism) and cognitive features (such as memory) 
largely fulfil the stated criteria, and while they are subject to state effects (Kendell & 
DiScipio, 1968), these are probably not of sufficient magnitude to invalidate them as 
endophenotypes. 
 
Necessity and benefit of categories 
 
Although it has long been argued that a dimensional classification system of 
psychiatric disorder would be more valid that a categorical one (Helzer et al, 2006), 
clinicians still need to make categorical decisions about treatment and, to a lesser 
extent, about diagnosis for wider social and legal purposes. Furthermore, the 
adoption of explicit diagnostic criteria and rule-based classification of mental 
disorders has had many benefits, including better diagnostic agreement and 
communication between clinicians and researchers, and better comparison of groups 
and outcomes (Lawrie et al, 2010). Despite these benefits, significant ‘boundary’ 
problems hamper both research and clinical practice (Kendell, 1982). 
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Utility: Boundary Difficulties in Practice 
 
At the unipolar/bipolar boundary there are at least six significant difficulties that 
complicate clinical practice and research, namely: poor diagnostic sensitivity to 
hypomania; so called “false unipolars”; an uncertain duration threshold for 
hypomania; the uncertain status of mixed episodes; the uncertain status of 
antidepressant induced mania; and the uncertain status of abnormal personality traits. 
1. Poor sensitivity 
 
It is difficult to reliably establish a history of hypomania, particularly in currently 
depressed patients (Andreasen et al, 1981; Dunner & Tay, 1993). However, 
systematic enquiry by adequately trained clinicians, interviewing family members 
and repeated interviewing can all increase sensitivity (Simpson et al, 2002; Benazzi 
& Akiskal, 2003a).  
2. “False Unipolars” 
 
Patients initially classified as unipolar often later develop an episode of hypomania 
or mania: Angst showed in a study of 406 patients with major mood disorders 
hospitalised at some time between 1959 and 1963 and followed-up until 1985, that 
about half the ‘unipolar’ patients, initially admitted with a depressive episode, 
convert to bipolar I or II disorder, while about half the ‘bipolar II’ patients progressed 
to bipolar I (Angst et al, 2005b). This conversion rate is in line with that of other 
studies (Akiskal et al, 1979, 1983b, 1995; Rao et al, 1995; Kovacs, 1996; Goldberg 




Figure 3 Proportion of patients who remain 'unipolar'; Goldberg, 2001. 
 
3. Uncertain Duration Threshold 
 
Current DSM-IV criteria for hypomania stipulate a minimum duration of 4 days, but 
epidemiologic data shows that most hypomanias are 1-3 days in duration (Wicki & 
Angst, 1991) and, on the basis of age of onset, depressive recurrence and familial 
bipolarity, a 2 day threshold is probably more appropriate (Cassano et al, 1992; 
Manning et al, 1997; Angst, 1998; Benazzi & Akiskal, 2001; Angst et al, 2003; Judd 
et al, 2003a). Technically these patients can be classified as “bipolar NOS”, but most 
research studies do not mention this group, and in practice they are often 
misclassified as ‘unipolar’ (Zimmermann et al, 2009).  In 153 children and 
adolescents with bipolar NOS, as a result of short (hypo)manic episodes, 40% went 
on to meet standard duration criterion within 2.5 years of follow up, and neither 
family history nor disability distinguished them from youth with BP I disorder 
(Axelson et al, 2006; Birmaher et al, 2009). DSM-5 work groups have stated that this 
finding will inform a recommendation to change the duration criterion (Mood 
Disorders Work Group, 2010). 
4. Mixed Episodes 
 
Kraepelin recognised depressive states with intercurrent manic symptoms. Non-
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euphoric manic symptoms, particularly irritability, distractibility and racing thoughts 
(Serretti & Olgiati, 2005) are frequently present during depressive episodes in 
patients with bipolar disorder (Akiskal, 1996; Akiskal & Pinto, 1999); however, 
“Unipolar” depressed patients with intercurrent manic symptoms tend to have a 
lower age of onset, more recurrence, stronger family histories of bipolar disorder and 
a poorer response to antidepressants, than those without (Benazzi & Akiskal, 2001; 
Sato et al, 2003; Balázs et al, 2006; Smith et al, 2009; Angst et al, 2011), suggesting 
they may be better classified as bipolar. It has been proposed that DSM-5 will 
eliminate the mixed-episode category (currently part of bipolar I disorder in DSM-
IV), in favour of a mixed features specifier - that can be applied to depressive, 
hypomanic and manic episodes (Mood Disorders Work Group, 2012a). 
5. Antidepressant induced mania 
 
DSM-IV currently excludes antidepressant-induced manic episodes from 
contributing to a diagnosis of bipolar disorder, despite family studies which indicate 
this may be part of a bipolar diathesis (Akiskal et al, 2003b; Akiskal & Benazzi, 
2003). It could be argued that a patient with a history of anti-depressant induced 
mania should be treated as if they had a bipolar disorder. It has been proposed that in 
DSM-5 current criteria should change, so that: “A full [hypo]manic episode emerging 
during antidepressant treatment (medication, ECT, etc) and persisting beyond the 
physiological effect of that treatment is sufficient evidence for a [hypo]manic 
episode diagnosis. However, caution is indicated so that one or two symptoms 
(particularly increased irritability, edginess or agitation following antidepressant use) 
are not taken as sufficient for diagnosis of a [hypo]manic episode.” (Mood Disorders 
Work Group, 2012b) 
6. Abnormal personality traits 
 
One of the most vexatious difficulties in clinical practice is differentiating between 
mood and personality disorder (PD) (Akiskal et al, 1983a). Studies of remitted 
inpatients with mood disorder detect PD in about 40% patients (Kay et al, 1999; 
Brieger et al, 2003), but during mood episodes this rises to around 60%, with 
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borderline PD the most prevalent Axis II diagnosis (Peselow et al, 1995; Schiavone 
et al, 2004), reflecting the overlap of affective symptoms in both categories. 
Borderline symptomatology in early-onset depression is predictive of later bipolar 
outcome (Akiskal et al, 1983b). 
 
“Atypical” depressive episodes (with features such as mood reactivity, interpersonal 
sensitivity and hypersomnia) are common in cyclothymia (Perugi et al, 2003), 
borderline PD (Skodol et al, 2002) but also in ‘unipolar’ patients who ultimately 
develop bipolar disorders (Akiskal et al, 1983b; Perugi et al, 1998). To complicate 
matters further, many episodes of hypomania lack classical euphoria, and are instead 
characterised by dysphoria and irritability (Akiskal et al, 2003a), while tension, 




Compelling longstanding theoretical objections to current mood disorder categories 
are accompanied by routine difficulties in their application. A dimensional 
conception may be more valid and/or useful. 
 
 
The Bipolar Spectrum 
 
Several Neo-Kraepelinian proposals for a dimensional or ‘spectrum’ approach to 
mood disorders have been advanced over the last three decades (Akiskal, 1983; 
Ghaemi et al, 2002, 2004a; Akiskal & Benazzi, 2006; Smith et al, 2008). 
 
In theory, any feature of manic-depressive illness could form the basis of a 





Importantly, discrete clinical disorders and continuous dimensions are not mutually 
exclusive concepts; both are compatible with a threshold model of disease (Kendell 
& Jablensky, 2003), and analysis of continuous variables increases power to detect 




If the assumption is made that manic symptoms are more severe than depressive 
symptoms, this allows one-dimensional proposals such as that by Ghaemi and 
Goodwin (Ghaemi et al, 2001). In this conception, bipolar NOS is replaced by 
“Bipolar Spectrum Disorder” (BSD) - that range of presentations with less manic 
symptoms than bipolar II disorder (see Figure 4). However this proposal does not 
address abnormal personality traits or mixed episodes, and it is hard to see how 
chronic MDD is less severe than atypical MDD, or that psychotic MDD is less severe 
than recurrent MDD. Furthermore, patients with MDD may be just as disabled as 
those with bipolar II disorder (Judd et al, 2008). 
 
 
MDE: Major depressive episode 
Figure 4 Ghaemi and Goodwin’s affective spectrum; Ghaemi, 2001. 
 
A more recent two dimensional model places proportions of depressive and manic 
symptoms on one axis, and severity on another (Angst, 2007). This model includes 
subsyndromal disturbance and has face validity; see Figure 5. 
 









Craddock proposed the use of four dimensions (Craddock et al, 2004) for measuring 
psychopathology (depression, mania, incongruence and psychosis) as an adjunct to 
categorical diagnosis. The Bipolar Affective Disorder Dimension Scale (BADDS) 
takes a lifetime historical approach, and generates an ordinal measure of severity 
(rather than a measure of symptoms per se) up until the time of the rating. The time 
required to administer the instrument probably restricts its use to research settings. 
 
Whilst no mood spectrum model has met with widespread acceptance, a two-
dimensional proposal by Angst appears to be superior, but is unlikely to help decision 
making in clinical practice. Those patients who are not at the extremes are likely to 




Reanalysis of the Epidemiologic Catchment Area (ECA) (Judd & Akiskal, 2003) and 
National Comorbidity Survey (NCS) databases (Merikangas et al, 2007) suggested 
that lifetime prevalence of BSD may be several times that of strictly defined bipolar I 
& II disorders. Recent re-analysis of the NCS replication sample indicates that BSD 
accounts for about a third of all patients with mood disorder (Angst et al, 2010, 
2011).  
 
In clinical practice, misdiagnosing a unipolar disorder in a patient on the bipolar 
spectrum can have serious consequences (Dunner, 2003) – the standard 
pharmacological treatment for unipolar disorder (anti-depressant monotherapy) is not 
recommended for the treatment of bipolar depression: not only is it poorly effective 
(Ghaemi et al, 2004b; Sidor & Macqueen, 2011), but there are risks of triggering 
mania (Wehr & Goodwin, 1987; Goldberg & Truman, 2003); precipitating treatment 
resistance (Sharma et al, 2005); and increasing suicidal behaviours (Akiskal et al, 
2005b). 
 
Failure to make the correct diagnosis also delays treatment. International studies 
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observe an average delay of eight years (see Figure 6) between the onset of a bipolar 
illness and the initiation of appropriate treatment (Baldessarini et al, 1999; Ghaemi et 
al, 1999, 2000; Baldessarini et al, 2003). Earlier age of onset is associated with 
longer delays in diagnosis (Berk et al, 2007), and the more years from symptom 
onset to first mood stabiliser use, the poorer the social functioning of the individual 
(Goldberg & Ernst, 2002). 
 
Figure 6 Delay in diagnosis of bipolar patients, from Ghaemi et al, 1999. 
  
Nevertheless, misdiagnosis is inevitable, particularly when treating high risk groups 
like young adults with recurrent depression (Smith et al, 2005b). Although up to half 
may go on to develop a frank bipolar disorder (Goldberg et al, 2001b), when seen, 
they are too early on in the course of their illness to establish a definitive diagnosis. 
However, there are some features which may predict bipolar outcome in apparently 
unipolar patients. 
 
Differentiating Unipolar and Bipolar Spectrum 
Depression. 
 
Neuropsychological, personality, genetic and clinical variables can in theory 




Neuropsychological research of mood disorders is complicated by many confounding 
factors – not only boundary problems, but also for example: state (vs. trait) effects, 
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illness severity and duration, polarity of the episode and presence or absence of 
psychosis, drug effects and substance abuse. 
  
Nevertheless it has been consistently demonstrated that subtle but widespread 
cognitive impairments of attention, learning, memory & executive function are a 
feature of both unipolar and bipolar disorders (Burt et al, 1995; Quraishi & Frangou, 
2002), in both symptomatic (Wolfe et al, 1987; Ravnkilde et al, 2002; Porter et al, 
2003; Martínez-Arán et al, 2004; Gruber et al, 2007) and remitted states (Cavanagh 
et al, 2002; Clark et al, 2002; Thompson et al, 2005; Goswami et al, 2006; Robinson 
et al, 2006; Hasselbalch et al, 2011). 
 
Cognitive deficits show a spectrum of severity, with most impairment in 
symptomatic bipolar I patients, and least in remitted unipolar depression. Deficits 
tend get worse with longer duration of illness (Robinson & Nicol Ferrier, 2006). 
Examination of patients with bipolar II (Torrent et al, 2006; Xu et al, 2011) and BSD 
demonstrated intermediate levels of impairment (Smith et al, 2006b).  
 
Cognitive impairment in the unaffected first degree relatives of patients with bipolar 
disorder, compared to controls, indicates that these deficits represent endophenotypes 
(risk traits), not just scarring or state effects (Gourovitch et al, 1999; Nicol Ferrier et 
al, 2004; Clark et al, 2005; Frantom et al, 2008). 
 
Whilst these cognitive differences are statistically significant across groups, they are 
of insufficient magnitude to be diagnostically useful, however as endophenotypes 




Kraepelin’s manic-depressive insanity included not only the continuum between 
bipolar and unipolar disorders, but also the relationship between the most severe 
forms of mood disorder and those that “pass over without sharp boundary into the 
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domain of personal disposition”. Kraepelin identified four “fundamental states” that 
he saw as constitutional or temperamental “rudiments of manic-depressive insanity” 
(Kraepelin, 1921, p. 118), namely depressive (dysthymic), manic (hyperthymic), 
cyclothymic, and irritable (which has no official contemporary analogue). 
 
Family and cohort evidence argued for the inclusion of cyclothymia within the group 
of mood disorders (Akiskal et al, 1977). The advent of DSM-III (Spitzer, 1981) led 
to the official recognition of cyclothymia and dysthymia as designated disorders 
(Akiskal, 2001) on Axis I (mental illness). As a result, previously poorly recognised 
groups of patients began receiving effective treatment (Silva de Lima et al, 2005; 
Baldessarini et al, 2011). “Hyperthymia” is not officially considered a clinical 
disorder; however there is evidence that patients with depressive disorders, that arise 
out of a hyperthymic temperament, tend to have stronger family histories of mania 
than those that do not (Cassano et al, 1992, 1999). 
 
How these threshold mood disorders relate to disturbances in personality or 
temperament is not clear, nor has consensus yet been reached on the number or 
content of dimensions needed to describe personality (Matthews et al, 2003). 
Eysenck has described three dimensions (Eysenck, 1959, 1967), the most studied 
being neuroticism (N) and extraversion-introversion (E). Previous studies of E and N 
in mood disorder have tended to be small and focus on highly selected groups (like 
in-patients or those attending tertiary referral clinics), fail to control for affective 
state and use a variety of different personality scales. Their results have often been 
contradictory. A recent Finish study (which assessed personality using the 57-item 
Eysenck Personality Inventory, whilst trying to control for affective state) found 
higher levels of N and lower levels of E in patients with BD and MDD compared to 
controls, but no statistically significant differences between patients with BD and 
MDD (Jylhä et al, 2010). Similarly, a recent UK study, using the Eysenck Personality 
Questionnaire – Revised Short Form (q.v. Chapter 4, page 65), distinguished cases 
from controls on N & E but, likewise, these measures did not differentiate bipolar 
from unipolar subjects (Smillie et al, 2009). One explanation for this failure might be 




Akiskal and colleagues have developed a temperamental evaluation tool which can 
be administered by questionnaire (Akiskal et al, 2005a, 2005c). When the 
temperaments of currently depressed bipolar and unipolar patients were compared, 
bipolar patient scored higher on measures of cyclothymic temperament (Mendlowicz 
et al, 2005), however a larger study of patients across the bipolar spectrum, using the 
same instrument, failed to find evidence of a gradient of temperament when 
confounders such as current mood state were taken into account (Di Florio et al, 
2010). 
 
A combination of inherited temperamental factors (harm avoidance, novelty seeking, 
reward dependence, persistence) and character factors (self-directedness, 
cooperativeness, self-transcendence) which arise during development (Cloninger et 
al, 1993), map onto Kraepelin’s fundamental states (Cloninger et al, 1998). In one 
study of depressed young adults, these factors did not distinguish those with and 
without BSD (Smith et al, 2005a).  
 
In summary, assessment of temperament/personality is feasible in currently 
depressed patients, but so far its role in distinguishing mood disorders is uncertain. It 




Whilst early family studies of mood disorder (before the mid-1960s) did not make 
the unipolar/bipolar distinction, they nevertheless provided strong evidence of 
familial aggregation of the broad phenotype of mood disorder (Tsuang, 1990). More 
recent twin and adoption studies (Craddock & Forty, 2006) clarify the relative 





Table 4 Genetic Epidemiology of Mood Disorders; Craddock and Forty, 2006. 
 
The heritability of unipolar depression (Sullivan, 2000) has been estimated at 31-
42%, and that of bipolar disorder (Craddock & Jones, 1999) may be as high as 80-
90%. How this genetic risk is transmitted is the subject of considerable controversy. 
If genes of large effect were commonly implicated, it is expected that linkage studies 
should have produced more consistent results. 
 
Candidate-gene association studies (which examine one or a few putatively involved 
genes) have been conducted on about 1% of those genes active in the brain during 
development and thereafter, but these studies have shown inconsistent results. More 
recently thousands of DNA samples, gathered by researchers from many centres, 
have been subjected to genome-wide association studies (GWAS) in both unipolar 
(Sullivan et al, 2008; Wray et al, 2012) and bipolar disorder (Sklar et al, 2008; 
Ferreira et al, 2008). 
 
Genetic studies are hampered by the nature of psychiatric disorder: clinical 
syndromes likely represent a heterogeneity of conditions with multiple genetic 
causes (Ginsburg et al, 1996). Furthermore, genetic abnormalities can have 
pleomorphic expression and are variably penetrant: for example, Huntington’s 
Disease, a disorder caused by a dominantly-inherited single-gene defect, can 
manifest with a wide variety of neuro-psychiatric presentations including anxiety, 
mood disorders and even psychosis, or no psychiatric symptoms at all (Jauhar & 
Ritchie, 2010). Furthermore, chromosomal abnormalities which segregate with 
psychiatric disorder (Blackwood et al, 2001; MacIntyre et al, 2003), and the 
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candidate genes identified in these families show associations that do not respect 
traditional diagnostic boundaries: for example, increasing risk for anxiety, mood and 
psychotic disorders (Knight et al, 2009).  
 
So far, a number of genes are implicated in mood disorder, including DISC1, 
CACNA1C, ANK3 (Barnett & Smoller, 2009; Gaysina et al, 2009; Sklar et al, 2011) 
and GPR50 (Thomson et al, 2004). Few clear findings have been replicated, 
suggesting that most genes involved are of modest effect size, and that even larger 
clinical samples may be required. Novel ways of defining phenotypes may aid 
genetics research (Craddock et al, 2004; Cross-Disorder Phenotype Group of the 
Psychiatric GWAS Consortium et al, 2009).   
 
Although psychiatric genetics may eventually clarify the pathogenesis of mental 
disorders, it is not yet useful in routine clinical practice. However, genetic analysis 
may help validate novel bipolar phenotypes. 
Clinical 
 
Cross-sectional and cohort studies have reliably identified clinical characteristics 
more common in bipolar than unipolar depression (Forty et al, 2008): male gender, 
early age of onset (Perris & D’ Elia, 1964; Weissman et al, 1996), bipolar and 
‘loaded’ family history, substance abuse, psychosis, diurnal variation, and shorter but 





Table 5 Differentiating bipolar and unipolar disorders by clinical characteristics; 
Akiskal, 2005. 
 
Excessive self-reproach, loss of energy and diminished libido are more common in 
unipolar depression (Akiskal, 2005; Bowden, 2005; Perlis et al, 2006a). Poor 
response to anti-depressant treatment may predict eventual bipolarity (Li et al, 2012). 
 
Recently published guidelines from the International Society for Bipolar Disorders 
Diagnostic Task Force have argued (Ghaemi et al, 2008) for a dimensional rather a 
categorical distinction between unipolar depression and bipolar disorder, and a 
‘probabilistic’ approach to diagnosis has been advocated (Mitchell et al, 2008), and 
had some early validation (Mitchell et al, 2011).  
 
Although clinical features may be suggestive, and probabilistic approaches are 
promising, they do not yet allow a definitive diagnosis. Neuropsychological features 
are too subtle, and our current understanding of genetics cannot aid clinical decision 
making. However, analysis of these features may provide external validation of novel 
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bipolar phenotypes.  
 
The Mood Disorder Questionnaire 
 
It has been argued that dimensional assessment of clinical features will aid diagnosis 
and research (Angst et al, 2005a; Nassir Ghaemi et al, 2005; Forty et al, 2008). 
 
The use of questionnaires to develop dimensional measures is well established. The 
Mood Disorder Questionnaire (MDQ) is a 15 item self-report checklist based on 
DSM-IV manic criteria, initially designed as a screening instrument for bipolar 
disorder (Hirschfeld et al, 2000) in a psychiatric outpatient population (Figure 7, 
overleaf). 
  
Extension of the use of the MDQ in large population samples (Hirschfeld et al, 
2003b, 2003a) has been criticised, mainly because, like all screening tools, its 
sensitivity is dependent on the base rate of the disorder in the sample (Zimmerman et 
al, 2004). The final item of the checklist was designed to elicit from the patient if the 
manic experiences caused any problems. This item reduced sensitivity in patients 
with poor insight; removing it increased sensitivity, without adversely reducing 
specificity (Miller et al, 2004). 
 
The main focus of this thesis was the assessment of the validity and utility of a 











1. A prospective clinical, cognitive and psychological follow-up study of young 
adults with an episode of DSM-IV major depressive disorder was conducted to 
determine the validity and the utility of the MDQ. 
 
2. Genetic samples, collected from the participants of the clinical study, were pooled 
with other samples collected locally, and a candidate-gene association study was 
conducted to test the validity of the BSD category.  
 
3. A cross-sectional population-based study to determine the validity of the MDQ 
was conducted using data from the Generation Scotland: Scottish Family Health 
Study. 
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Bipolar disorder is often initially misdiagnosed (Zimmermann et al, 2009), with an 
average of around 8 years delay in making the correct diagnosis (Ghaemi et al, 
1999). Earlier age-of-onset is associated with longer delays in diagnosis (Berk et al, 
2007) and delayed treatment results in poorer outcomes (Goldberg & Ernst, 2002). 
Young adults with a major depressive episode are at high risk of misdiagnosis (Smith 
et al, 2005b). Furthermore, the boundary between unipolar and bipolar disorders is 
uncertain and failures to find zones of rarity between different disorders or even 
between ‘normality’ and ‘disorder’ (Kendell & Jablensky, 2003) have led to disease 
‘spectrum’ models (Angst, 2007). Dimensional measures of mania like the Mood 
Disorder Questionnaire (MDQ) (Hirschfeld et al, 2000) may help clarify the validity 
of the bipolar spectrum concept, and ultimately improve our ability to detect 
important clinical differences. The validity and utility of the MDQ in young adults 
presenting with an episode of major depression depressive disorder was unknown. It 
was hypothesised that in those with a DSM-IV diagnosis of Major Depressive 
Disorder, the MDQ would correlate with external validators of bipolar disorder. To 
be clinically useful, the MDQ would require predictive validity (Kendell, 1989). A 





Recruitment of participants 
Patients 
 
All patients (n=64) were recruited from the psychiatry clinic serving the University 
Health Centre (UHC). Over 90% of students at Edinburgh university are registered 
with a general practitioner at the UHC. 
 
Over a twenty-one month period, between May 2005 and January 2007, 314 referrals 
were made by General Practitioners (GPs) at the UHC of patients with a working 
diagnosis of depression. All patients were clinically assessed by the author and 
eligibility was determined. 
Controls 
 
Study participants were asked to volunteer friends who had no personal history of 
depression to act as controls. Thirteen controls were recruited in this way. Additional 
controls were recruited from medical students attending teaching at the Royal 




The work was approved by Lothian Research Ethics Committee and participants 






Patients were determined to be eligible if: 
 
1. they were currently suffering from an episode of DSM-IV major depressive 
disorder, with either a Hamilton Depression Rating Score of at least 15 or a Beck 




2. they were younger than 25 or had had at least one previous episode of DSM-IV 
major depression before the age of 25. 
 
Patients were excluded if they had poor English or a previous serious head injury. 
 
These criteria are slightly broader than a previous study in this population (Smith et 
al, 2005b), which excluded those with a single episode of depression, and used a 
lower maximum age-of-onset, at 22 years.  
 
From the original 314 referrals to the clinic, 217 (69%) attended and were assessed. 
Of those who were assessed, 72 (33%) were eligible. Of those seventy-two, 8 
declined to participate, but 64 (89%) agreed, gave written informed consent, and 
provided baseline data. All patients were given treatment as usual and followed up at 
least monthly by the author. 
 
Forty-eight (75%) patients stayed in follow up at 3 months and provided outcome 
data. 
 






The core diagnostic assessment was made using the Structured Clinical Interview for 
DSM-IV-TR (First et al, 2002). 
 
Overall severity of current episode was recorded according to the Clinical Global 
Impression of Illness scale (CGI) (Guy, 1976). Current mood state was assessed 
using the 17-item Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960), the 
Montgomery and Åsberg Depression Rating Scale (MADRS) (Montgomery & 
Asberg, 1979), the Young Mania Rating Scale (YMRS) (Young et al, 1978), and the 
Beck Depression Inventory (BDI) (Beck et al, 1961). 
 
‘Bipolarity’ was assessed by: Ghaemi’s novel diagnostic criteria (Ghaemi et al, 2002) 
for bipolar spectrum disorder; a 15-item hypomania checklist (Angst et al, 2003; 
Smith et al, 2005b) and the first thirteen items of the MDQ (Hirschfeld et al, 2000). 
 
Family history was elicited using the structure of the Family Interview for Genetic 
Studies (FIGS) (Maxwell, 1992). 
 
Substance use was assessed using the Drug Abuse Screening Test (DAST-20) 
(Skinner, 1982) and the Alcohol Use Disorders Identification Test (AUDIT) 
(Saunders et al, 1993). 
 
The Global Assessment of Functioning (GAF) component of DSM-IV-TR (ibid), the 
social problem questionnaire (SPQ) (Corney, 1988), and the 12-item version of the 
Short Form Health Survey (SF-12) (Ware et al, 1996) were used to assess 
psychosocial functioning. Life events during the preceding 6 months were elicited 
using a modified version of the List of Threatening Experiences – Questionnaire 
version (LTE-Q) (Brugha & Cragg, 1990). 
 
Physical symptoms were elicited using a modified version of the UKU [Committee 




Beliefs about medicines were elicited using the Beliefs about Medicines 
Questionnaire (BMQ) (Horne et al, 1999), while adherence was estimated using the 




Intelligence was estimated using the National Adult Reading Test (NART) (Nelson & 
Willison, 1991). The NART is a measure of pre-morbid verbal IQ, and is highly 
correlated with full-scale IQ. 
 
As noted in Chapter 1, impairments of attention, learning, memory & executive 
function are a feature of both unipolar and bipolar disorders, and show a spectrum of 
severity, with most impairment in symptomatic bipolar I patients, and least severity 
in remitted unipolar depression. Patients with bipolar II and “bipolar spectrum 
disorder” demonstrate intermediate levels of impairment. Attention has a widespread 
impact on cognitive function. 
 
In the present study the domains of executive function, memory and attention were 
assessed, using a fixed-order series from the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) (Robbins et al, 1994, 1998): Spatial recognition 
memory (SRM) is predominantly a test of visual memory. Paired associates learning 
(PAL) is a test of visual memory and learning. Verbal recognition memory (VRM) is 
a test of verbal memory. Five-Choice Reaction Time (RTI) is a test of sustained 
attention and psychomotor speed. Spatial Span (SS), Spatial Working Memory 
(SWM) and Stockings of Cambridge (SoC) are test of executive function, working 
memory, and planning. The tests were administered in the following order: SRM, 
PAL, VRM – immediate, RTI, SSP, SWM, SOC and finally VRM – delayed.  All 







Personality was evaluated with the Temperament Evaluation of the Memphis, Pisa, 
Paris and San Diego Autoquestionnaire (TEMPS-A) (Akiskal et al, 2005c) and the 
125 item Temperament and Character Inventory (TCI-125) (Cloninger, 1994). 
 
The timing of data collection at recruitment and at follow up are tabulated in Table 6. 
 
Measure t=0 t=3/12 
SCID x  
HDRS x x 
MADRS x x 
YMRS x x 
BDI x x 
MDQ x  
FIGS x  
DAST-20 x  
AUDIT x  
GAF x x 
SPQ x  
SF-12 x x 
LTE-Q x  
UKU-SE x x 
BMQ x x 
MARS-5  x 
NART x  
CANTAB x x 
TEMPS-A x  
TCI-125 x x 
Table 6 Timing of data collection 
Data Analysis 
 
An alpha level of .05 was used for all statistical tests. Where stated, when there was 
prior evidence of a relationship, one-tailed tests were used; otherwise 2-tailed tests 
were used. Change in GAF, BDI and HDRS were assessed by calculating 
proportional change. 
 
Differences between means were assessed by independent-sample t-test, or one-way 
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independent analysis of variance (ANOVA) as appropriate. Non-parametric data 
were analysed with the Mann-Whitney test, or Kruskal-Wallis test as appropriate. 
Continuous data were subject to bivariate Pearson’s correlation.  
 
Cohen’s conventions for effect size (Cohen, 1992) were used throughout. Analysis 




The demographic characteristics and substance use history of the whole sample are 
displayed in Table 7, along with the depressive symptoms and severity measures of 
the patients.  
 
 patients 
n = 64 
controls 
n = 32 
female n(%) 39 (60.9) 19 (59.4) 
Caucasian n(%) 56 (87.5) 26 (81.3) 
age: M (SD) 22.6 (3.76) 23.3 (3.99) 
age at onset: M (SD) 16.7(2.85)  
in a relationship n(%) 29 (45.3) 22 (68.8) 




























IQ: M (SD) 117.0 (5.22) 117.9 (3.70) 
AUDIT: M (SD) 7.92 (5.35) 6.19 (3.35) 
DAST-20: M (SD) 1.23 (2.08) 0.34 (0.70) 
HDRS: M (SD) 21.7 (5.21)  
BDI: M (SD) 27.9 (9.18)  
CGI: M (SD) 4.44 (0.53)  
GAF: M (SD) 44.5 (11.0)  
Table 7 Demographics, substance use and symptom severity 
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The distribution of total scores of the first thirteen items of the MDQ, by gender, is 
displayed in Figure 8. 
 
Figure 8 Histogram: MDQ total score by gender 
Clinical Characteristics 
Clinical characteristics of the sample are displayed in Table 8.  
 
  combined 
n = 64 
   MDQ HCL 
 
seMDD 
n = 7 
rMDD 
n = 57 



















MDD FHx          nil 
2nd degree 
1st degree 













































Adverse reaction  No 























seMDD – single episode; rMDD – recurrent; FHx: family history 
Table 8 Baseline clinical characteristics and the MDQ and HCL 
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Novel Criteria for BSD 
 
Novel criteria for bipolar spectrum disorder were applied to the sample and the 
results are shown in Table 9.  
 
 
 seMDD rMDD comb 
n(%) 
MDQ HCL test 
df = 62 
r 
























t = 4.84 
p < .001 
.52 










t = 6.03 












 t = 5.41 
p < .001 
.57 
p (two-tailed) < .001 in bold; equal variances not assumed; 
seMDD – single episode; rMDD – recurrent; comb – combined sample 




Clinical and psychological correlations 
 
To further explore the validity of the use of the MDQ as a continuous measure of 
bipolarity, Pearson’s correlations were conducted with continuous clinical variables, 
temperament and personality measures, and symptoms measures suggestive of 
adverse reaction to antidepressant treatment; see Table 10. 
 
 
MDQ HCL Pearson’s correlations at t = 0 
n = 64 r p r p 
Age of Onset -.077 .273‡ -.143 .129 
Number of episodes  .259 .019
‡
 .226 .036 
Clinical 
Length of episode (n=37) .050 .767‡ -.235 .162 





Harm Avoidance .084 .512 -.006 .965 
Self Transcendence .453 <.001* .352 .004* 
Cooperativeness .013 .918 .026 .839 
Persistence .107 .201‡ .221 .040‡ 
Reward Dependence -.163 .197 -.120 .345 
TCI-125 
Self-Directedness -.128 .313 -.130 .307 
Anxious .110 .387 .140 .272 
Cyclothymic .427 <.001* .369 .003* 
Depressive .000 .998 .021 .868 




 .092 .235 
restlessness .102 .271 .163 .164 
agitation -.116 .244 -.054 .373 
decreased sleep -.085 .306 -.048 .387 




n = 38 
suicidal thoughts -.098 .283 .013 .471 
‡one-tailed test; p < .05 in bold; *p < .01 




Case-control cognitive differences 
 









M(SD) t-test p r 
NART IQ 117.0 (5.22) 117.9 (3.70) 0.08‡ .431  
SRM 78.6 (13.1) 79.7 (13.3) 0.40 .692  
PAL 10.1 (7.9) 9.6 (9.4) 0.27 .785  
VRM 8.4 (2.0) 8.9 (1.7) 1.26 .212  
5CRT 323.0 (52.58) 301.3 (34.4) 2.11 .037 .21 
5CMT 364.4 (136.3) 284.9 (53.7) 4.03
‡
 .018 .39 
SS 7.1 (1.6) 7.7 (1.4) 1.76 .081  
SWM 15.7 (15.7) 13.6 (13.7) 0.63 .530  
SoC-ITT 11617 (6411) 9601 (6084) 1.46 .146  
SoC-PS 10.11 (1.5) 9.81 (1.6) 0.909 .366  
SRM: Spatial Recognition Memory; PAL: Paired Associate Learning; 
VRM: Verbal Memory – immediate free recall; 5CRT: 5 Choice Reaction Time; 
SS: Spatial Span; SWM: Spatial Working Memory - between errors; 
SOC-ITT: Stockings of Cambridge initial thinking time; 
SOC-PS: Stockings of Cambridge problems solved. 
‡equal variances not assumed; p < .05 in bold 






Correlations between cognitive measures and the MDQ and HCL were conducted 
and are displayed in Table 12 
 
MDQ HCL Pearson’s r 
t = 0 (n = 62) r p r p 
SRM .053 .685 .206 .108 
PAL‡ -.106 .418 -.042 .746 
VRM‡ .011 .932 .116 .372 
5CRT -.302 .017 -.223 .082 
5CMT -.030 .817 -.008 .954 
SS .157 .223 .172 .181 
SWM -.114 .337 -.155 .230 
Soc-ITT‡ .086 .510 .008 .953 
SRM: Spatial Recognition Memory; PAL: Paired Associate Learning; 
VRM: Verbal Memory – immediate free recall; 
5CRT: 5 Choice Reaction Time; 5CMT: 5 Choice Movement Time; 
SS: Spatial Span; SWM: Spatial Working Memory - between errors; 
SOC-ITT: Stockings of Cambridge initial thinking time; 
SOC-PS: Stockings of Cambridge problems solved. 
‡n=61; p < .05 in bold 




Outcome at three months 
 
After recruitment the author, along with the patient’s usual GP, treated the depressed 
patients in the usual manner, and followed them up at least monthly. Forty-eight 
(75%) of the original 64 participants stayed in follow up and donated outcome data. 
Thirty-six patients (75%) were taking unopposed antidepressant medication (i.e. 
without a mood stabiliser) at 3 months. Correlations are presented in Table 13. 
 
MDQ HCL t=3/12 
r p r p 
GAF change .265 .072 .104 .486 
HDRS change  -.138 .351 -.178 .226 
clinical 
n=48 
BDI change -.081 .583 -.176 .230 
restlessness .393 .009* .268 .057 
agitation .121 .241 .037 .415 
decreased sleep .205 .115 .266 .059 




suicidal thoughts .338 .022 .391 .009* 
‡one-tailed test; p < .05 in bold; *p < .01 





The clinical sample, drawn from patients registered at the University Health Centre, 
is fairly affluent. The control sample is well matched in terms of age, years education 
IQ and social class. Lower scores on measures of alcohol consumption (AUDIT), 
and drug use (DAST-20), than one would expect from anonymous surveys in this 
population probably represent under-reporting. In terms of severity measures, the 
patients were moderately depressed and impaired, as would be expected in a 
secondary care out-patient clinic. 
   
The sample were predominantly female. As the gender ratio of bipolar disorder is 
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equal, but females predominate in unipolar disorder, it was hypothesised that men 
would score higher than women on the MDQ. No patients scored 12. On average, 
men scored higher (M = 6.44, SD = 2.92) than women (M = 4.36, SD = 3.00) on the 
MDQ, t(62) = 2.74, p (two-tailed) = .008, and gender represented a medium effect, 





The majority of patients (89.1%) had a recurrent depressive disorder. Younger age at 
onset, and greater recurrence has been reported in bipolar patients. In the current 
sample, the small number of patients 7 (10.9%) with a single depressive  
episode had a later age of onset (M = 19.9, SD = 3.02), than those with a previous 
episode (M = 16.4, SD = 2.61). This was a significant t(62) = 3.30, p = .002, and 
moderate effect, r = .39, and is in line with previous findings. The combined sample 
age of onset (M = 16.7, SD = 2.85) was roughly a year older than that in the previous 
study (Smith et al, 2005b). 
 
Patients with bipolar disorder tend to have higher rates of atypical depressive 
features, and 12 (18.8%) participants met criteria for DSM-IV atypical subtype at 
recruitment. It was hypothesised that those with atypical depression would score 
higher on the MDQ (M = 5.50, SD = 2.75), than those without (M = 5.10, SD = 3.21) 
however there was no significant difference, t(62) = .402, p = .689. 
 
No patients in the sample had a first degree relative with bipolar disorder, but most 
(79.7%) had a first or second degree relative with depression. Patients with a single 
episode of depression reported fewer family members with histories of mood 
disorder, than those with recurrent depression, as expected. Both unipolar and bipolar 
disorder probands are know to have high familial levels of depression and, across 
groups of family history, neither MDQ, F(3, 60) = 0.51, p = .68, nor HCL, F(3, 60) = 
0.02, p = .99, varied significantly. Sixteen patients (25%), all with recurrent 
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depression, had three or more first-degree relatives with mood disorder, or were from 
families with three successive generations with mood disorder (so called “loaded” 
pedigrees, more common in bipolar probands), but they did not differ significantly on 
the MDQ score, t(62) = .299, p = .77, or HCL, t(62) = .167, p = .87, from those 
without a “loaded” family history. 
 
One previous study found a trend for higher levels of deliberate self-harm (DSH) in 
bipolar patients (Parker et al, 2005) and, in the current sample, patients with a history 
of DSH tended to score slightly higher on the MDQ (M = 5.30, SD = 3.52), than 
those without (M = 5.03, SD = 2.66), but there was no significant effect, t(62) = 
0.345, p = .731. 
 
Adverse reaction to previous antidepressant treatment was reported by 12 (18.8%) 
patients, who tended to score higher on the MDQ (M = 6.25, SD = 3.86) than those 
who had not reported this problem (M = 4.92, SD = 2.90), but a failure to record 
which patients were antidepressant naïve prevented further analysis. 
 
Novel Criteria for BSD 
 
Only three patients (4.7%), all with recurrent depression, fulfilled Ghaemi’s criteria 
in this sample. This is significantly fewer than might be expected from a previous 
study in this population (Smith et al, 2005b), which found a prevalence of BSD of 
36.9%, however that cohort had an earlier age of onset, and did not include those 
with single-episode depression. 
 
Patients with bipolar disorder often struggle to recognise their manic symptoms as 
pathological. The original categorical criteria of the MDQ (score of 7 or more, 
occurring at the same period of time, impairing function) were found to have low 
sensitivity, partly because bipolar patients tended not to endorse the impairment 
criterion, and it has been suggested that this should be removed (Miller et al, 2004). 
Fourteen (21.9%) patients scored positive on the MDQ original criteria, while a 
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further 10 patients were positive with the impairment criterion removed (“MDQ7” in 
the table), giving a total of 24 (37.5%). All patients who scored 7 or more also 
endorsed the “same period of time” criterion, so this was not discriminatory. An 
alternative measure, the clinician-elicited 15-item hypomania checklist (HCL) has a 
threshold of 8 or more for a diagnosis of BSD. Twenty-two (34.4%) patients were 
positive for BSD by this measure. Patients who were positive for the MDQ and 
“MDQ7” scored significantly higher on the HCL, and conversely those who were 
HCL positive scored much higher on the MDQ. These were all large effects, r > .5. 
 
In the previous study (Smith et al, 2005b), 10% of participants had a first degree 
relative with bipolar disorder, whilst in this sample no patients were in this category. 
In the current investigation, rates of depressive disorder in 1st degree relatives were 
also lower, at almost two thirds, compared with over three-quarters in the earlier 
study. The low prevalence of Ghaemi’s BSD in this study could indicate poor inter-
rater reliability for Ghaemi’s criteria, but the absence of bipolar family history, and 
lower rates of depression in 1st degree relatives in this sample could reflect broader 
entry criteria, changes in referral pattern or random fluctuations. However, it should 
be noted that using the MDQ (with and without the severity criterion) and the HCL, 
the prevalence of BSD was comparable with the previous study (ibid), at between 
one and two-fifths of the sample. 
 
Clinical and psychological correlations 
 
As the known age-of-onset in bipolar disorder is, on average, lower than in unipolar 
depression, it was hypothesised that there would be an inverse correlation between 
MDQ and age-of-onset. There was a small inverse correlation, r = -.077, but this was 
not significant, p (one-tailed) = .27. The relatively young age, and narrow age range 
(M = 22.6, SD = 3.76) of the sample may explain the lack of any association. 
 
As bipolar disorder tends to be more highly recurrent than unipolar disorder, it was 
hypothesised that number of depressive episodes would show a positive correlation 
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with MDQ. There was a small to medium positive correlation, r = .259, and this was 
significant, p (one-tailed) = .019; a very similar finding was also seen with the HCL. 
 
Brief major depressive episodes (less than 3 months) are one of Ghaemi’s criteria for 
BSD. It was hypothesised that there would be an inverse correlation between MDQ 
and length of current depressive episode, however there was no significant effect 
with either the MDQ, r = .05, p (one-tailed) = .38, or the HCL. In practice, it was 
often difficult for patients to recall the duration of their current depressive episode. 
The lack of any significant correlation may represent the methodological weakness 
of retrospective collection of this information.  
 
Temperament and Character Inventory: TCI-125 
 
Studies have found that Cloninger’s personality dimension, Novelty Seeking (NS), is 
higher in patients with bipolar compared to unipolar disorder (Young et al, 1995; 
Evans et al, 2005). It was hypothesised that there would be a positive correlation 
between NS and MDQ. There was a highly significant, p (one-tailed) = .003, positive 
correlation, r = .34. This was a moderate effect. 
 
It was predicted (Cloninger et al, 1998) that Self Transcendence (ST) would be 
associated more strongly with bipolar than unipolar depression, and this finding has 
recently been reported (Harley et al, 2011). In the current sample a significant 
moderate positive correlation was seen between ST and MDQ, r = .453, p (one-
tailed) <.001, and a very similar correlation was also found with the HCL. 
 
Several studies found higher levels of Harm Avoidance (HA) in bipolar, compared 
with unipolar patients (Young et al, 1995; Evans et al, 2005; Harley et al, 2011) but 
these trends were not statistically significant. In the current sample there was no 
sizeable or significant correlation between HA and MDQ or HCL. The distribution of 
HA was negatively skewed, with the modal score equal to the maximum possible 
score of 20. Correction of negative skew by reflection and log transformation did not 
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materially alter the result (see Appendix 1). In a previous study (Smith et al, 2005a), 
harm-avoidance measured during euthymia in this population was also high, but not 
statistically different between ‘pure’ unipolar and BSD groups, but TCI Persistence 
(P) was higher in the BSD group. It was hypothesised that P would be correlated with 
MDQ. Although there was a small, significant, correlation between HCL and P, there 
was no sizeable or significant correlation with MDQ.  
 
It has been predicted that low Cooperativeness (C) and low Self-Directedness (SD) 
are more unipolar than bipolar (Cloninger et al, 1998), and while in one study, a BSD 
group did show a non-significant trend in that direction (Smith et al, 2005a) another 
found the converse (Evans et al, 2005). In the current sample there was no sizeable 
or significant correlation between C, SD and either the MDQ or HCL. 
 
Several studies (Evans et al, 2005; Smith et al, 2005a; Harley et al, 2011) have found 
no difference in Reward Dependence (RD) between unipolar and bipolar groups; in 




The TEMPS-A has been analysed in patients with bipolar and unipolar disorder in 
several studies recently reviewed by Di Florio (Di Florio et al, 2010); in general, 
bipolar patients tended to score higher than unipolars on the cyclothymia and 
irritable subscale and, in this large study, patients with bipolar II scored higher than 
those with bipolar I disorders. As a whole the bipolar group scored higher than 
unipolars on the hyperthymic scale, and this was consistent with several previous 
findings (Gassab et al, 2008; Mazzarini et al, 2009). Analyses of the dysthymic and 
anxious scales have not shown consistent results. 
 
It was hypothesised that MDQ would positively correlate with the cyclothymia, 
hyperthymia and irritable scales of the TEMPS-A. There was a highly significant 
positive correlation of moderate effect with cyclothymia, r = .427, p (one-tailed) < 
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.001; a moderate positive correlation with irritability, r = .316, p (one-tailed) = .005; 
and a small positive correlation with hyperthymia: r = .200, p (one-tailed) = .057. 
These result persisted after controlling for depressive (BDI) and manic symptoms 
(YMRS) by partial correlation, and the association with hyperthymia increased 
slightly in size , r = .240, and strengthened in significance, p (one-tailed) = .031 (see 
Appendix 2).  
 
The use of unopposed anti-depressants in unrecognised bipolar disorder may be 
associated with switch to mania, poor tolerance of antidepressants, increase in 
suicidal ideation and poor response (McElroy et al, 2006).  It was hypothesised that 
in those taking antidepressants at recruitment (n=38), the MDQ would positively 
correlate with adverse effects of antidepressants, however, there were no sizeable 
correlations or any approaching one-tailed significance. 
 
Case-control cognitive differences 
 
Patients with bipolar disorder tend to show more severe cognitive deficits than those 
with unipolar disorder. It was hypothesised that patients would show significant 
impairment compared to controls on neuropsychological measures administered by 
the CANTAB touch screen computer, and that, in the patient group, MDQ would 
correlate with impairment.  
 
Comparison of depressed patients, versus controls, detected moderate differences on 
five-choice reaction time and small differences on movement time: controls 
responded and moved more quickly than patients. No other differences were 
detected. Although cognitive deficits have been detected between similar groups of 
patients and controls, even in remitted subjects (Smith et al, 2006b), these tests were 
traditional, well validated, paper and pencil tests. Using the CANTAB system in 
young adults, several authors have failed to show differences between controls and 
unipolar depressed patients (Purcell et al, 1997; Sweeney et al, 2000). Another 
possible confounding factor was the above-average IQ of the sample. During data 
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collection the author observed that some quite profoundly depressed patients were 





It was a priori hypothesised that, in the patient group, MDQ would correlate with 
neuropsychological measures administered by the CANTAB touch screen computer. 
Although there was a moderate negative correlation, r = -.302, p (two-tailed) = .017, 
with reaction time, there were no other effects that were sizeable or approaching 
significance, which may not be surprising, given the paucity of case-control 
differences. 
 
Outcome at three months 
 
The MDQ and HCL were not correlated with outcome at 3 months, but interestingly 
there was a moderate, highly-significant positive correlation between MDQ and 
restlessness, and a similar effect approaching significance with HCL. Furthermore, 
there was a moderate, significant, positive correlation between MDQ and suicidal 
thoughts, and this was supported by a similar correlation with HCL. 
 
Strengths and limitations 
 
The main potential limitations of this study were a lack of any external biological 
validator, the relatively small sample size, and the highly selected population from 
which the sample was drawn. The fact that some patients had been initiated on drug 
treatment at recruitment reduced the ability of the study to examine drug effects. The 
relatively high social status of the sample could be seen as a weakness; on the other 
hand, cases and controls were drawn from the same fairly homogenous population, 
and this increased the likelihood of detecting real differences. Furthermore, young 
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adults are a high-risk group for bipolar disorder, and they also have the most to lose 
if they are diagnosed or treated inappropriately, so the relatively young age of the 




This study supports the observation that manic symptoms are continuously 
distributed in depressive patient populations (Cassano et al, 2004), and indicates that 
young adults presenting with a major depressive episode have sub-DSM-IV threshold 
manic symptoms which are non-the less of clinical relevance (Smith et al, 2009). It 
emphasises the need to routinely probe for historical manic experiences, and suggests 




A prospective clinical, cognitive and psychological study of young adults, presenting 
with an episode of DSM-IV Major Depressive Disorder, examined the validity of a 
questionnaire-based dimensional measure of historical manic symptoms, and 
compared it to a clinician elicited checklist. The prevalence of BSD in this sample 
was 4.7% using Ghaemi’s criteria, 34% using the checklist and 22% using the 
questionnaire. Removing the impairment criterion from the MDQ increased the 
prevalence of BSD to ~37%. The prevalence of Ghaemi’s criteria BSD was lower 
than expected: this could be partially explained by slightly different inclusion 
criteria, or may indicate poor inter-rater reliability. Higher scores on the MDQ were 
significantly associated with male gender, recurrence, greater number of episodes, 
novelty seeking, self-transcendence, cyclothymic and irritable temperament, faster 
reaction time, and (in patients taking unopposed antidepressants) greater restlessness 
and suicidal thinking at 3-month follow-up. Effect sizes were small or moderate. The 
checklist was highly correlated with the questionnaire, and they tended to show very 
similar associations. This provides evidence that the MDQ, and to a lesser extent the 
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HCL, are valid measures of bipolarity in young adults with a DSM-IV diagnosis of 
MDD. 
 
An attempt to test the validity of the bipolar spectrum concept by external biological 
means, in this case genetic analysis, will be examined presently in Chapter 3. The 





Chapter 3: Genetic association of mood disorder 




   
Candidate gene studies, and more recently, genome-wide association studies 
(GWAS) have identified a number of loci containing variants predisposing to bipolar 
disorder including: DISC1, CACNA1C, ANK3 and DTNBP1 (Barnett & Smoller, 
2009; Gaysina et al, 2009; Sklar et al, 2011). The melatonin-related G protein-
coupled receptor 50 (GPR50) is located on Xq28, a region previously implicated in 
linkage studies for bipolar disorder (Massat et al, 2002). RNA in situ hybridisation 
experiments with human GPR50 detected expression in the mediobasal 
hypothalamus (in a region containing the ventromedial and arcuate nuclei), the 
paraventricular nucleus, and in the infundibular stalk (Reppert et al, 1996); 
expression was also detected in the pituitary gland. The combination of map position 
on Xq28 and expression pattern makes GPR50 a positional and functional candidate 
in affective disorder (Thomson et al, 2004). 
 
G protein-coupled receptors (GPCRs) mediate transmembrane signal transduction in 
response to ligand binding, linking interactions between the cell and the environment 
(Lundstrom, 2006). The GPR50 gene encodes a protein of 617 amino acids that is 
45% identical to the melatonin receptors MT1  and MT2. Despite this close 
relationship, the GPR50 receptor does not bind to melatonin, and no biological 
ligand has been identified (i.e. it is an “orphan receptor”). The GPR50 receptor does 
however heterodimerise with MT1 and MT2, resulting in the inhibition of MT1 
signalling (Levoye et al, 2006). GPR50 is most highly expressed in the 
paraventricular nucleus, the infundibular stalk and in the mediobasal hypothalamus, 
in a region containing the ventromedial and arcuate nuclei; it is expressed in foetal 
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and adult brain (Reppert et al, 1996; Drew et al, 2001). The expression pattern 
suggests a role in the neuroendocrine system. However, recent identification of 
neurite outgrowth inhibitor, Nogo-A, as a protein interaction partner, and subsequent 
identification of a neurite outgrowth phenotype in neurons over-expressing GPR50, 
suggest that it may have a role in neuronal development (Grünewald et al, 2009). A 
study at the University of Manchester with GPR50 knockout mice showed a 
hyperactivity/metabolic phenotype - see Figure 9. (Ivanova et al, 2008). 
 
 
Representative, double-plotted wheel-running activity records from wild-type (top) 
and GPR50 knockout (bottom) mice spanning an 8-day period. The white and black 
bar below the activity records represents the light and dark phases of day, 
respectively. GPR50 knockout mice exhibited significantly higher activity (mean 
wheel revolutions/day) than did the wild-type mice (n = 6/genotype, *P < 0.05).  




Of three human studies investigating GPR50 in psychiatric illness, the first, which 
examined patients with schizophrenia, bipolar disorder, recurrent major depression 
and controls (Thomson et al, 2004), found a significant association between an 
insertion-deletion polymorphism (∆502-505) and bipolar disorder in a sample of 264 
patients (with bipolar I or II disorder) and 562 controls (p = .007). As GPR50 is sex 
linked, the sample was divided by gender, resulting in a stronger association in 
females (p = .00023), but no significant association in men. The strength of the 
association was further increased when the female patients, who fulfilled Ghaemi’s 
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criteria (Ghaemi et al, 2002) for bipolar spectrum disorder, were combined with the 
bipolar I and II sample (p = .000026). In that study, association was also detected 
between MDD in females and both ∆502-505 (p = 0.044) and a non-synonymous 
single-nucleotide polymorphism (SNP) rs13440581 (p = 0.018), but those results did 
not withstand correction for multiple testing (ibid).  
   
A second study in a smaller Swedish cohort of patients with bipolar disorder failed to 
replicate the ∆502-505 findings (Alaerts et al, 2006), while in a Hungarian sample of 
children and adolescents which grouped MDD and BD together, no association was 
found with three markers (Feng et al, 2007), one of which (rs561077) was in 
complete linkage disequilibrium (LD) with the ∆502-505 polymorphism in the 
Scottish population. It is possible that the later two studies were unable to detect 
association due to genetic heterogeneity between populations, or lack of power. 
Although, the studies appeared to be correctly powered to repeat the initial finding, 
multiple studies have shown that subsequent replication studies often result in a 
reduced estimate of the effect size, with fewer than half of primary studies being 
strongly replicated: the so-called “winner's curse” (Lohmueller et al, 2003). 
 
An attempt to replicate the Thomson et al. study in an independent sample follows. 
One additional marker, rs1202874, recently reported to be associated with 
significantly elevated plasma triglycerides and lowered HDL-cholesterol levels 
(Bhattacharyya et al, 2006). Most studies suggest a closer link between coronary 
heart disease risk and hypertriglyceridaemia among women than among men 
(McBride, 2008). Female patients with mood disorder have been found to have 
elevated triglycerides levels, and low HDL-C to other cholesterol ratios (Sagud et al, 
2009); in that sample, those with bipolar disorder had significantly higher 
triglyceride levels than both those with MDD and controls. A similar gradient 
(bipolar > MDD > controls) of cardiovascular and cerebrovascular disease has also 
been demonstrated (Baune et al, 2006). It was therefore decided that, although we 





The author collected DNA donated by the patients and controls described in Chapter 
2 and, along with others, an additional larger sample. Laboratory analysis of the 
DNA was performed by others. The author analysed the data and, along with others, 
wrote the subsequent paper.  
 
The study was designed and carried out in 2008-09, before results of genome wide 
association studies in bipolar disorder, schizophrenia and depression had been 
published. However it is relevant to note that the X chromosome has not been 
adequately analysed in current GWAS, and the association data available on X-linked 
genes is from relatively small case-control studies, as described here.  
Method 
Recruitment of Participants  
Patients 
Out-patients were recruited from those attending general psychiatry clinics in the 
East of Scotland. Participants were eligible if they fulfilled DSM-IV criteria for 
MDD or BD. Subjects with a history of head injury or a primary diagnosis of 
personality disorder were excluded. A currently depressed, early-onset subset (n=56) 
was recruited as described in Chapter 2. A previously recruited subset of early-onset 
MDD patients (Smith et al, 2005b) including 27 females positive for bipolar 
spectrum disorder (BSD) by Ghaemi’s criteria were included. In total, 365 subjects 
with BD, and 379 with MDD were recruited.  
Controls 
Eight hundred and eighty four unscreened (population) blood samples were obtained 
from the Scottish Blood Transfusion Service and from general practices in the East of 
Scotland. Twenty-nine controls were recruited as described in Chapter 2. 
Ethical Approval 
All subjects gave informed consent in writing before participating. The project was 






The additional patients had diagnostic assessment performed by the author and other 
experienced psychiatrists using the SADS-L (Schedule for Affective Disorders and 
Schizophrenia – Lifetime version  (Endicott & Spitzer, 1978)) along with case note 
review. Diagnoses were made according to DSM-IV-TR criteria. Blood was taken for 
genotyping. Age at onset was defined as the age when the subject first consulted a 




To investigate this gene further, and because GWAS generally have not included 
sufficient coverage of single-nucleotide polymorphisms (SNPs) in this region of poor 
linkage disequilibrium (LD), four SNPs used in the previous study (Thomson et al, 
2004) were genotyped, spanning the GPR50 gene region: rs561077, rs13440581, 
rs2072621 and rs529386. For the ∆502-505 polymorphism, Taqman technology was 
used. Genotyping was performed by others at the Wellcome Trust Clinical Research 
Facility, Genetics Core in Edinburgh. In the initial association study (Thomson et al, 
2004) the ∆502-505 polymorphism was genotyped using fluorescently labelled 
polymerase chain reaction (PCR) products, separated on an automated laser 
fluorescence DNA sequencer, ABI 3730. To validate the methodology, 40 samples 
used in the original study were genotyped using the Taqman method. This gave 
100% concordance. In addition, the SNP rs561077 is in very high (complete) LD 
with the ∆502-505 polymorphism (D’ = 1, r2 = 0.998), providing a second validation 
method for the ∆502-505 genotype call. One additional marker, rs1202874, recently 
reported to be strongly associated with abnormal lipid metabolism (Bhattacharyya et 




Data Analysis   
 
Case-control association analyses were performed using Haploview (Barrett et al, 
2005) and χ2 goodness of fit test for single markers and BD, MDD and subgroup. 
100,000 permutation were used to correct for multiple testing. Linkage 
disequilibrium analysis showed that SNP, rs1202874, was not in LD with any of the 
five remaining polymorphisms (r2 < 0.05). All markers were tested for Hardy-
Weinberg equilibrium (HWE) using a χ2 goodness of fit test. All markers were in 
HWE (p > 0.05) in the control sample. 
 
Clinical phenotype and treatment response were subjected to ANOVA for continuous 
variables and Fisher’s exact test for categorical variables. Significant associations 
were examined post-hoc with Tukey’s t-test. Two-tailed test and an alpha level of .05 




The association analysis results are displayed in Table 14 Associations that might 
have been expected between rs13440581 or ∆502-505 and mood disorder were not 
replicated, even when females were considered alone.  
 
The intronic SNP rs1202874 (which had not been genotyped in the original study, but 
had been added because of its association with abnormal lipid metabolism) showed 
nominally significant association with BD in females (p = .0035; OR 1.9, 95% CI 
1.2-3.0), which remained significant after correction for multiple testing (permuted 
p = .037). When 29 female MDD patients, who fulfilled Ghaemi’s criteria for BSD 
were included in a joint analysis with the female bipolar cases, as previously 
performed (Thomson et al, 2004), this association became stronger, giving a highly 
significant result (p = .0014; OR 1.97, 95% CI 1.26-3.06) which remained significant 
after correction for multiple testing (permuted p = .0035). Initial associations were 
also observed (p = 0.037) in females with MDD, and in the combined male and 
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female BD sample (p = .0157) with the same SNP, but these were no longer 
significant (p > 0.05) after correction for multiple testing.  
   
As mentioned above, there was no significant association between the ∆502-505 
polymorphism and any disorder, regardless of gender. Access to the original sample, 
yielding a combined sample size of 336 females with BD, and 542 female controls 
allowed a joint analysis. In the combined sample (Pippa Thompson, 2008, personal 
communication), significant association between females with bipolar disorder and 
the deletion polymorphism of ∆502-505, gave p = .0006 (permuted p = .0024) but 
with reduced effect size (OR 1.41, 95%CI 1.16-1.71).  
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  All Male Female    
Markera Group pc frequency nb pc frequency nb pc frequency nb χ2 OR 95%CI 
Deletion/Insertion CTL  40.0 1206  41.5 620  38.4 586    
 BD ns 41.6 531 ns 38.6 145 ns 42.7 386    
 MDD ns 43.4 574 ns 49.3 144 ns 41.0 430    
              
rs529386 (A/G) CTL  64.0 1167  61.9 599  66.2 568    
 BD ns 60.7 532 ns 62.5 144 0.052 60.1 388    
 MDD ns 64.9 562 ns 66.2 136 ns 64.6 426    
              
rs561077 (A/G) CTL  60.1 1187  59.0 607  61.2 580    
 BD ns 58.3 511 ns 62.6 139 ns 56.7 372    
 MDD ns 55.8 556 0.054 50.0 138 ns 57.7 418    
              
rs1202874 (C/T) CTL  9.0 1194  10.8 614  7.1 580    
 BD 0.0157 12.0 533 ns 13.1 145 0.0035 12.6 388 8.52 1.9 1.20 - 3.01 
 MDD ns 9.9 558 ns 7.0 142 0.0370 10.8 416 4.31 1.59 1.00 - 2.54 
 BD+BSD na na na na na na 0.0014 13.0 446 10.19 1.97 1.26 - 3.06 
              
rs2072621 (A/C) CTL  44.2 1174  42.4 602  46.2 572    
 BD ns 45.8 528 ns 42.4 144 ns 47.1 384    
 MDD ns 42.8 561 ns 41.0 139 ns 43.4 422    
              
rs13440581 (A/G) CTL  40.3 1173  40.1 609  40.6 564    
 BD ns 41.8 512 ns 38.2 144 ns 43.2 368    
 MDD ns 37.6 550 ns 37.1 140 ns 37.8 410    
aAllele listed first has frequency shown; bNumber of chromosomes; cuncorrected p value 
CTL: control; BD: bipolar disorder; BSD: bipolar spectrum disorder; MDD: major depressive disorder 
Table 14 Association study between GPR50 markers and mood disorder 
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Genotype data was successfully acquired for 53 of the patients described in Chapter 
2. Thirty-five (66%) were female, and their associations with the minor allele of the 
rs1202874 SNP and the deletion polymorphism are displayed in Table 15, overleaf. 
Group number were small. Patients carrying the deletion had, on average, a younger 
age of onset, and reported more episodes of depression, but these differences were of 
marginal statistical significance. Patients carrying the minor C allele of rs1202874 
had, on average, a longer reaction time. No association remained statistically 
significant after Bonferroni’s correction for multiple testing. 
 
Discussion  
   
An association between BD and an intronic SNP, rs1202874, in GPR50 was detected. 
As in the previous study of the Scottish population (Thomson et al, 2004), 
association was restricted to females (p = 0.0035, OR = 1.9, 95%CI 1.2-3.0), and 
increased when a subgroup of MDD meeting Ghaemi’s criteria for BSD were 
included (p = 0.0014, OR 1.97, 95% CI 1.3-3.1), providing some predictive validity 
for the concept of bipolar spectrum disorder.  
 
Rs1202874 was not tested in the original study of the Scottish population, and due to 
a lack of LD across GPR50, it could not be imputed. This SNP has previously been 
associated with significantly elevated plasma triglycerides and lowered HDL-
cholesterol levels (Bhattacharyya et al, 2006). Most studies suggest a closer link 
between coronary heart disease risk and hypertriglyceridaemia among women than 
among men (McBride, 2008). Female patients with mood disorder have been found 
to have elevated triglycerides levels, and low HDL-C to other cholesterol ratios 
(Sagud et al, 2009); in that sample, those with bipolar disorder had significantly 
higher triglyceride levels than both those with MDD and controls. A similar gradient 
(bipolar > MDD > controls) of cardiovascular and cerebrovascular disease has also 



















age at onset 17.4(2.2) 15.42(2.4) 2.19 .036 16.0(2.00) 15.9(2.71) 0.08 .938 
episodes MDD 2.78(1.56) 5.69(4.19) 2.02 .052 4.22(1.72) 5.19(4.41) 0.64 .528 
         
MDQ 3.11(1.54) 4.73(3.41) 1.92 .064 3.44(3.05) 4.62(3.12) 0.98 .337 
HCL 3.67(2.40) 5.58(3.33) 1.58 .124 4.11(3.22) 5.42(3.18) 1.06 .295 
         
Novelty seeking 7.67(4.18) 7.81(3.20) 0.11 .917 6.67(2.34) 8.15(3.67) 1.13 .266 
Self Transcendence 2.56(2.74) 3.31(2.26) 0.82 .421 2.56(1.74) 3.31(2.56) 0.82 .421 
Persistence 1.67(1.80) 1.94(1.79) 0.40 .694 1.56(1.59) 1.98(1.85) 0.62 .543 
         
Cyclothymia 5.67(2.83) 4.50(2.96) 1.03 .310 3.78(2.59) 5.15(3.00) 1.32 .206 
Irritability 0.89(0.93) 1.69(1.64) 1.38 .176 1.11(0.78) 1.62(1.70) 0.85 .400 
         
five-choice RT 315.9(55.6) 334.7(62.2) 0.80 .429 374.9(66.4) 314.2(50.6) 2.86 .007 
five-choice MT 353.9(101.6) 386.9(163.5) 0.57 .575 387.1(112.2) 375.4(162.1) 0.20 .843 
MDD: major depressive disorder; MDQ: mood disorder questionnaire; 
HCL hypomania checklist;  RT: Reaction Time; MT: Movement Time; 
RS: rs1202874; C: cytosine; T thymine; uncorrected p < .05 in bold 
Significant differences were found between those homozygous for the ∆502-505 insertion polymorphism, compared to ins-del and del-del combined on age-of-onset, 
and number of episodes. Five-choice reaction time was significantly shorter in those homozygous for thymine at rs1202875, compared with heterozygotes and the 
individual homozygous for cytosine. 
Table 15 Clinical, personality and neuropsychological features, by genotype 
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The reported association with the ∆502-505 insertion/deletion polymorphism and 
bipolar disorder was not replicated in this sample. However, combining the ∆502-505 
data from both studies did detect significant association with a nominal p value in 
combined data, p = .0006, and permuted p = .0024, but with a reduced effect size 
compared to the original report (OR 1.41 and 95% CI 1.16-1.71). The lack of 
replication in the smaller follow-up studies by others may be due to population 
differences, or to a lack of power; both had low power to detect modest effects. 
Likewise the difference in signal between the two Scottish samples, as with other 
attempts to look at association between this locus and affective disorders, may be as 
a result of ascertainment bias, genetic heterogeneity between individuals with BD, or 
the relatively small sample sizes. 
   
Despite the lack of any overall association between the ∆502-505 deletion and 
bipolar disorder, analysis of the early onset depression subset, described in Chapter 
2, detected an earlier age of onset of illness (p = 0.036), and a greater number of 
episodes of depression (p = 0.052) in deletion carriers. Reaction-time was 
significantly slower in carriers of the C allele at rs12012875, and slower in deletion 
carriers, but this latter difference was not statistically significant. Had the overall 
study found an association, the subset results would have provided evidence of 
predictive validity for the BSD category. In the current circumstances, the subset 
result is difficult to interpret. Deletion carriers also scored, on average, higher on the 
MDQ and HCL, but this finding was not statistically significant. In any case, the very 
small sample size suggests these findings must be treated with caution.  
   
Overall, the failure to replicate an association between a ∆502-505 deletion and 
bipolar disorder makes it difficult to interpret findings in the highly phenotyped 
subset. Until the genetics of bipolar disorder is more firmly established, association 
studies will not be able to provide convincing validation or refutation of the bipolar 
spectrum concept (Kelsoe, 2003); conversely, genetic analysis of phenotype across 
traditional diagnostic boundaries studies may provide the insight needed to 




The new finding of an association between bipolar disorder and a SNP implicated in 
abnormal lipid metabolism is biologically attractive, and may warrant further 




Chapter 4: A Dimensional Measure Of Mania, In A 




In Chapter 2, an analysis of a traditionally defined unipolar out-patient sample 
provided some clinical and psychological evidence of concurrent and predictive 
validity of two dimensional mania measures (one interview–based and the other 
questionnaire–based), in a moderate sized sample of young adults. It was uncertain if 
these finding would be replicated in more representative sample of the population. 
 
The Generation Scotland: Scottish Family Health Study (GS:SFHS) is population-
based family cohort (n≅24 000) which was in recruited over the 7 years from 2004 to 
2011 (www.generationscotland.org). The aim was to create a resource for genetic 
studies of common disorders of public health importance (Smith et al, 2006a). One 
of the three main themes of the biobank is ‘mental health’, which includes mood 
disorder and cognition. 
 
In this chapter, the validity the MDQ was examined in a group of participants from 
GS:SFHS with and without lifetime diagnoses of MDD. It was hypothesised that if 
the MDQ was a valid measure of bipolarity, higher scores on the MDQ would be 
associated with features more common in bipolar than unipolar disorder, such as an 
earlier age of onset, greater recurrence, and more cognitive impairment.  
 
Two major dimensions of personality have been extensively investigated in mood 
disorder: neuroticism and extraversion-introversion. Eysenck described neuroticism 
as a “largely inherited” general measure of emotionality (Goodwin & Jamison, 2007, 
329) and this construct has been studied as a potential indicator of bipolar disorder. 
Results have been contradictory: some studies have indicated that unipolar patients 
score higher on levels of neuroticism (Hirschfeld & Klerman, 1979), but studies 
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designed to show differences between unipolar and bipolar disorders failed to show 
differences between groups (Perris, 1971; Matussek P, 1983). Nevertheless, both 
dimensions were measured in the Generation Scotland cohort and this provided an 
opportunity to examine their relationship with the MDQ. 
 
The analysis also offered the opportunity to examine the reliability and internal 
structure of the MDQ in the Scottish population. Analysis of the MDQ has been 
conducted using principal component analysis (PCA) followed by orthogonal 
(varimax) rotation (Harman, 1976) in recovered outpatients with mood disorder 
(Benazzi & Akiskal, 2003b), in community samples (Mangelli et al, 2005), in stable 
mood disorder patients in Hong Kong (Chung et al, 2008) and Spain 
(Sanchez‐Moreno et al, 2008), in pregnant Iranian women without severe 
depression (Barekatain et al, 2008), Polish patients with major depressive disorder 
(MDD), half of whom were treatment-resistant (Kiejna et al, 2010) and in depressed 
out-patients in Brazil (Leão & Del Porto, 2012). These studies have described fairly 
similar internal structures: two factors§ have been identified repeatedly: ‘energised-
activity’ and ‘irritable-thought racing’. However these studies could be criticised for 
using arbitrary cut-off eigenvalues to determine the number of factors. Furthermore it 
may not be appropriate to assume a priori that the factors do not correlate, and if so, 




Participants were recruited at random from primary care patient lists (initially in 
Glasgow and Tayside, but latterly from Ayrshire, Arran and North-East Scotland), 
and were eligible to participate if they were aged between 35 and 65 and had at least 
one first degree relative, age 18 or over, who would also participate. As each 
                                                 
§ The term “factor” is widely used in the literature to describe components, and the terms are used 
interchangeably throughout this text, however this is not strictly correct: PCA and factor analysis are 




participant was enrolled, they were invited to indicate a further first-degree relative 
who might be prepared to participate, with the aim of “snowballing” recruitment to 
maximise family size. 
 
Ethical framework 
The methods of participant identification, recruitment, access and commercialisation 
policies were developed with wide-spread public consultation (Haddow et al, 2008). 
Ethical approval was given by Tayside NHS Committee on Research Ethics 
(reference 05/S1401/89). 
Data collection 
Participants completed a multiple-choice questionnaire, including the MDQ 
(Hirschfeld et al, 2000), before visiting a clinic. At the clinic visit they underwent a 
session lasting about 2 hours which included physical measurements, biological 
sampling and personality and cognitive tests. 
 
Trained researchers administered the screening questions of a structured diagnostic 
interview and, if the screen was positive, the mood sections of the SCID-I (First et al, 
2002), slightly modified by the author. The SCID elicited presence or absence of 
lifetime history of MDD, age of onset, and number of depressive episodes.  
 
Scales Used 
Extraversion and neuroticism were measured with the Eysenck Personality 
Questionnaire-Revised, Short Form (EPQ-RSF)  (Eysenck et al, 1985). Verbal 
declarative memory was assessed with the Logical Memory (LM) test, immediate 
and delayed, from the Wechsler Memory Scale III (Wechsler, 1998a). Information 
processing speed was tested with the Digit Symbol (DS) substitution test from the 
Wechsler Adult Intelligence Scale III (Wechsler, 1998b). Executive function was 
assessed with a letter-based Verbal Fluency (VF) test (Lezak, 1995). Verbal ability 
was measured with the Mill Hill Vocabulary (MHV) Test (Raven et al, 1977). 
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Current levels of psychological distress were assessed with the 28-item General 
Health Questionnaire (GHQ-28), which consists of 4 subscales designed to assess: 
(A) somatic symptoms, (B) anxiety and insomnia, (C) social dysfunction and (D) 
‘severe depression’ (Goldberg & Hillier, 1979). 
 
Quality Control  
All new researchers received group training in the administration of the SCID from 
the author, and ongoing refresher sessions throughout the study. Senior research 
nurses at each site received extra training from the author and acted as local mentors, 
and trained researchers discussed borderline cases with the author as they presented. 
A short local training video (see Appendix) was created to supplement the official 
SCID videos and training manual. Anonymised digital audio recordings of sequential 
clinic sessions were made, and were reviewed (blind to database diagnosis) by the 
author, with the assistance of another trained psychiatrist. Inter-rater reliability for 
the presence or absence of a lifetime diagnosis of major depressive disorder was 
good: κ = 0.86 (p < .001), 95% CI (0.7, 1.0) in the quality control sample (n = 58). 
 
Sample 
The data available for analysis was from 2942 participants who had completed the 
MDQ, 610 (20.7%) of whom had received a research diagnosis of major depressive 
disorder (MDD), and the remaining 2332 who had screened negative for psychiatric 
disorder. A small number who screened positive, but did not receive a SCID 
diagnosis were excluded (n = 21).  
 
Data Analysis 
Reliability was assessed using Cronbach’s α. Principal component analysis (PCA) 
was conducted with oblique (direct oblimin) rotation. A Monte-Carlo simulation 
(parallel analysis) using raw data permutation (O’Connor, 2000) was conducted to 




Group differences between means were assessed by one-way independent analysis of 
variance (ANOVA) as appropriate. As group sizes were unequal, to avoid type I 
error, the conservative Welch F was calculated. Equal variance could not be 
assumed, so conservative post-hoc Games-Howell t-tests were conducted. 
Continuous data were subject to Pearson’s bivariate and partial correlation as stated. 
 
An alpha level of .01 was used for omnibus tests, and an alpha level of .05 was used 
for post-hoc tests and the parallel analysis. Two-tailed tests were used. Cohen’s 
conventions for effect size (Cohen, 1992) were used. Analysis was conducted using 





Psychometric Properties of the MDQ 
Reliability 
In terms of the reliability (internal consistency) of the MDQ, a Cronbach’s α 
coefficient of .85 was observed. Individual item – total correlations ranged from .35 
to .62, overall very similar to results seen in a US general population study 
(Hirschfeld et al, 2003b). Inter-item correlations are displayed in Table 16. 
 
MDQ item 1 2 3 4 5 6 7 8 9 10 11 12 13 
1 hyper ---             
2 irritable .305 ---            
3 confident .345 .279 ---           
4 less sleep .263 .198 .330 ---          
5 talkative .358 .304 .402 .333 ---         
6 racing .241 .340 .314 .285 .359 ---        
7 distracted .299 .360 .303 .258 .369 .444 ---      .000 
8 energy .333 .241 .502 .375 .424 .309 .315 ---      
9 active .310 .247 .500 .360 .417 .330 .338 .721 ---     
10 outgoing .344 .167 .301 .212 .269 .178 .228 .275 .262 ---    
11 sex .321 .239 .407 .271 .310 .256 .277 .354 .378 .365 ---   
12 risky .381 .267 .319 .238 .274 .270 .299 .254 .289 .356 .402 ---  
13 spending .247 .218 .206 .184 .214 .233 .224 .164 .178 .207 .236 .327 ---       
r > .3 underlined; r > .5 in bold 
Table 16 R – Matrix: MDQ Inter-Item Correlations 
 
 
Increased energy levels, increased activity, and increased self-confidence were 
particularly highly correlated. 
 
Internal factor structure 
Monte Carlo simulation, using raw data permutation was conducted and scree plots 
were drawn for the combined sample, controls alone and MDD cases alone (see  
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Appendix 3). When the combined sample was examined, 3 factors appeared to 
provide the best fit (initial eigenvalues 4.73, 1.19, 1.08), but when controls and cases 
were separated, 2 factors appeared more appropriate for controls (initial eigenvalues 
4.64, 1,19), and 3 factors more appropriate for cases (initial eigenvalues 4.38, 1.30, 
1.10). Principal component analyses are displayed in Table 17, overleaf. 
 
In controls, the first factor comprised increased energy and activity measures, but 
also included racing thoughts, irritability and distractibility. A second ‘disinhibited’ 
factor was found which was comprised of those criteria which asked about taking 
risks or impulsivity. Previous studies which have included healthy controls 
(Sanchez‐Moreno et al, 2008) or population samples (Mangelli et al, 2005) have 
not analysed controls separately, so no previous data is available for comparison. 
 
In the combined sample, and in participants with MDD, a three factor structure was 
detected. Again, the largest factor loaded heavily onto energised and activity items, 
while a second factor loaded predominantly on racing thoughts, distractibility and 
irritability. A third factor emerged which included risk taking/impulsivity criteria and 
‘feeling so good or so hyper’. An ‘energised-activity’ factor has been consistently 
found in analyses of the MDQ and in other mania self-rating scales (Bauer et al, 
1991; Forty et al, 2010), however previous studies of the MDQ, which have all 
reduced the scale to two factors, have tended to include irritable/racing thoughts 
items, or disinhibited/risk-taking items, or a mixture of both in a second factor in an 
inconsistent manner. It is possible that this inconsistency might be resolved if a 3 










  Factor Factor Factor 
Item 
 
uC 1 2 3 
 
uC 1 2 
 
uC 1 2 3 
8 much more energy .703 .871 -.019 .003 .740 .825 -.054 .653 .842 .038 .029 
9 much more active .711 .845 -.008 .035 .749 .807 -.018 .636 .839 .080 -.021 
3 much more self-confident .687 .612 .205 .044 .715 .626 .167 .637 .449 .010 .372 
5 much more talkative .656 .446 .076 .339 .657 .661 .044 .612 .382 .355 .135 
4 less sleep didn’t miss it .549 .495 .054 .149 .535 .636 -.089 .607 .377 .085 .339 
6 thoughts raced .579 .172 -.077 .724 .551 .630 -.060 .536 .149 .797 -.096 
7 easily distracted .602 .135 .032 .681 .597 .554 .099 .508 .110 .771 -.075 
2 irritable .518 -.023 .084 .690 .498 .446 .103 .442 -.146 .562 .226 
12 foolish or risky .589 -.041 .732 .104 .560 -.002 .758 .601 -.115 .123 .728 
10 much more social .521 .131 .740 -.211 .492 -.031 .703 .567 .113 -.140 .692 
11 much more sex .620 .296 .571 -.077 .653 .237 .554 .573 .143 -.114 .653 
1 so good or so hyper .606 .143 .535 .124 .561 .215 .483 .662 .160 -.008 .591 
13 spending money .431 -.226 .543 .302 .369 -.074 .592 .457 -.180 .280 .491 
rotated sums of squares loadings  3.57 3.18 2.80  4.28 3.09  2.86 2.53 3.37 
rotated principal components loading < .4 in grey > .5 in bold 
uC: first unrotated component; Factor: rotated component 






Of 620 participants with a history of MDD, 317 (51%) had experienced a single 
depressive episode (seMDD). Of the remainder 206 (33%) had a recurrent course 
(rMDD), with a range of between 2 and 20 episodes. The SCID interview elicits 
number of previous depressive episodes but has a residual category within recurrent 
MDD in which episodes are either ‘too numerous or indistinct to count’; ninety-
seven (~16%) participants fell into this category, referred to as chronic/recurrent 
(crMDD) hereafter. 
  
The frequencies with which participants in each group endorsed individual 
statements of the MDQ are displayed in Table 18 . 
 










  2322 (78.9) 317(10.8) 206 (6.9) 97(3.3)  
1 hyper 137(5.9) 41(12.9) 32(15.5) 32(33.0) 119.3 
2 irritable 534(23.0) 140(44.2) 109(52.9) 62(63.9) 191.7 
3 confident 471(20.3) 78(24.6) 59(28.6) 34(35.1) 20.2 
4 less sleep 424(18.3) 59(18.0) 59(26.7) 35(36.1) 26.6 
5 talkative 320(13.8) 73(23.0) 67(32.5) 41(42.3) 104.1 
6 racing 591(25.5) 148(46.7) 132(64.1) 69(71.1) 243.1 
7 distracted 493(21.2) 141(44.5) 117(56.8) 62(63.9) 244.0 
8 energy 422(18.2) 68(21.5) 47(22.8) 32(33.0) 16.1 
9 active 468(20.2) 81(25.6) 58(28.2) 40(41.2) 32.4 
10 outgoing 67(2.9) 19(6.0) 12(5.8) 19(19.6) 74.4 
11 sex 197(8.5) 45(14.2) 45(21.8) 17(17.5) 48.6 
12 risky 157(6.8) 43(13.6) 43(20.9) 35(36.1) 137.7 
13 spending 93(4.0) 39(12.3) 41(19.9) 28(28.9) 173.3 
  subset n = 1277  
 n (%) 855 (67.0) 197(15.4) 151(11.8) 74 (5.8)  
B same time 424(49.6) 137(69.5) 115(76.2) 61(82.4) 74.0 
p < .001 in bold 
Table 18 Proportion Endorsing Individual MDQ items 
  
A gradient in score (control < seMDD < rMDD < crMDD), was observed across 




Criterion B: “If you ticked YES to more than one of the above, have several of these 
happened during the same period of time?” could only validly be endorsed by those 
scoring more than 1 on the MDQ (n=1322), however in 45 individuals data was 
missing, leaving 1277 subjects. In that subset, the proportion endorsing the ‘same 
time’ criterion showed a gradient across the groups (control < single episode MDD < 
recurrent MDD < chronic/highly recurrent MDD). The non-euphoric manic 
symptoms of irritability, distractibility and racing thoughts (which made up the 
second factor of the MDQ in the patient group) were most frequently endorsed, in 
line with previous findings (Hirschfeld et al, 2000). 
 
It appeared that the more recurrent the depressive disorder, the more likely 
individuals were to report manic symptoms, and this could indicate that manic 
symptoms are a marker of severity of MDD (Cassano et al, 2004), however it is also 
likely that some participants within the MDD category were suffering from 
unrecognised bipolar II disorder (Angst et al, 2011; Smith et al, 2011). 
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Clinical, personality and cognitive findings  
Clinical 
 
MDQ scores were positively skewed (see Appendix 4). In the recurrent MDD group, 
mean MDQ was significantly higher in men than in women but there were no 
significant differences between genders within the seMDD or crMDD groups. Both 
correction by log transformation, and non-parametric analysis with Mann-Whitney 
U-test, gave the same material result. MDQ scores by gender are displayed in Table 
19. 
 
 male:female m:f male M(SD) female M(SD) t p r 
control 985:1337 1:1.4 2.28 (2.91) 1.59 (2.35) 6.24 < .001 .14 
seMDD 111:206 1:1.8 3.27 (3.18) 2.96 (2.60) 0.932 .352  
rMDD 86:120 1:1.4 4.83 (3.29) 3.35 (3.04) 3.27 .001 .23 
crMDD 35:62 1:1.8 5.09 (3.64) 5.29 (3.61) 0.267 .791  
equal variances not assumed; p ≤ .001 in bold 
Table 19 Mean MDQ scores by gender 
 
As the female to male ratio is lower in bipolar than unipolar disorder, this result  
provides some evidence of antecedent validity of the MDQ. In the control sample 
MDQ was higher in men than women. This was a small but highly significant effect. 



















 n(%)     
 2322(78.9) 317(10.8) 206(7.0) 97(3.3)     
female 1337(57.6) 206(65.0) 120(58.3) 62(63.9)     
MDQ≥7 186(8.0) 39(12.3) 46(22.3) 29(29.9) χ 2 = 87.9 <.001   
GHQ>4 264(11.5) 66(21.2) 96(47.1) 49(52.1) χ 2 = 273.7 <.001   
 M(SD)     
age 52.4(13.7) 45.6(13.5) 48.2(12.4) 46.8(12.2)     
age/onset --- 34.7(11.7) 31.0(12.1) 24.6(10.2) F(3, 607) = 33.8 <.001 B>C>D .28 
MDQ Total 1.88(2.6) 3.07(2.8) 3.97(3.2) 5.22(3.6) F(3, 2938) = 64.1 <.001 A<B<C<D .29 
         
EPQ N 2.96(2.76) 5.07(3.19) 6.89(3.22) 8.04(3.03) F(3,2929) = 201.8 <.001 A<B<C<D .44 
EPQ E 7.76(3.48) 7.73(3.38) 6.22(3.92) 5.78(4.00) F(3, 2929) = 16.7 <.001 A,B>C,D .14 
         
LM-I 15.9(4.03) 16.3(3.59) 16.0(4.19) 14.9(3.91) F(3, 2929) = 3.17 .024   
LM-D 14.7(4.46) 15.2(3.88) 14.8(4.38) 13.7(4.07) F(3, 2916) = 3.33 .020   
VF 40.0(11.7) 40.8(11.6) 41.0(12.4) 40.6(11.6) F(3, 2911) = 0.81 .487   
DS 70.1(16.6) 72.9(16.0) 72.2(15.9) 68.6(15.2) F(3, 2920) = 4.01 .008 A<B,C,D .06 
MHV 30.6(4.65) 30.2(4.74) 30.8(5.05) 29.8(5.11) F(3, 2905) = 1.64 .181   
         
GHQ A 0.64(1.32) 1.02(1.65) 1.78(1.97) 1.96(2.20) F(3, 2904) = 35.8 <.001 A<B<C,D .25 
GHQ B 0.45(1.14) 0.84(1.55) 1.75(2.22) 2.34(2.61) F(3, 2905) = 43.2 <.001 A<B<C,D .32 
GHQ C 0.42(1.10) 0.77(1.63) 1.66(2.17) 2.27(2.44) F(3, 2904) = 42.2 <.001 A<B<C,D .31 
GHQ D 0.07(0.49) 0.21(0.90) 0.82(1.67) 1.75(2.54) F(3, 2903) = 28.5 <.001 A,B<C<D .15 
GHQ Total 1.51(2.84) 2.63(3.92) 5.20(5.25) 6.56(6.13) F(3, 2903) = 58.8 <.001 A<B<C,D .35 
p < .01 in bold; seMDD: single episode MDD; rMDD: recurrent MDD; crMDD: chronic/recurrent MDD;  
LM-I: logical memory immediate; LM-D: logical memory delayed; VF: verbal fluency; 
DS: digit symbol; MHV: Mill Hill Vocabulary; F: Welch F; ‡Games-Howell t-tests, p < .05 




Age of onset was highest in the single episode group (M = 34.7, SD = 11.7) and, on 
average, 10 years lower in the chronic/highly recurrent group (M = 24.6, SD = 10.2). 
Interestingly, although age-of-onset was unimodally distributed in the other groups, 
in the crMDD group (n = 96) there was a suggestion of a trimodal distribution 
(Figure 11), and furthermore a trimodal distribution of MDQ scores was seen in this 
group. 
 




Several studies (Bellivier et al, 2001; Bellivier, 2003; Perlis et al, 2004; Lin, 2006; 
Manchia et al, 2008) have reported that bipolar I aggregates into three sub-groups on 
age of onset, broadly speaking ‘early’ with a mean of 17 years; ‘mid’ with a mean of 
about 26, and ‘late’ with a mean between 35 and 46 years, and these finding have 
been replicated recently in the UK, in the largest sample to date (n = 1369) 
(Hamshere et al, 2009). 
 
Perlis and colleagues (Perlis et al, 2006a) analysed data from participants in large 
multicentre trials of major depression and bipolar I disorder, which ascertained 
episode number using the SCID: 40% of the bipolar I group had episodes that were 
‘too numerous or indistinct to count’, compared with less than 5% of the MDD 
subjects. In the present study 97 (16%), of those 620 with MDD, were in the crMDD 
sub-category, and this group also had the earliest age of onset. It was predicted the 
MDQ would be highest in this group, and this proved to be the case. This provides 
some concurrent evidence of the validity of the MDQ.  
 
Neuroticism and Extraversion 
Neuroticism (N) was highest in the chronic/highly recurrent group (M = 8.04, SD = 
3.03), lower in the group with recurrent depression, followed by single episode 
MDD, with controls showing the lowest levels of N (M = 2.96, SD = 2.76). All 
differences were statistically significant. N shows a weak relationship with short term 
(3-6 month) outcome, but more strongly predicts poor 1 year (Scott et al, 1995), 
longer term outcome (Mulder, 2002), and chronicity, when defined as depressed for 
at least 24 months in the previous 4-5 years (Wiersma et al, 2011). In this 
longitudinal Dutch cohort study, low E was also a strong predictor of chronicity. In 
the present sample E was lower in the rMDD and crMDD groups, compared to 
seMDD and controls. 
 
In the current study N, and to a lesser extent E, appear to differentiate cases from 





In terms of cognitive function, no statistically significant differences were found 
between groups on verbal ability, verbal memory or executive function. The groups 
showed a small (r = .06) but statistically significant difference on digit symbol 
substitution test (processing speed); post-hoc comparisons indicated that controls 
were faster at performing the task than participants with a history of MDD. This 
finding is in accord with other research (Xu et al, 2012). 
 
Psychological Distress 
The GHQ-28 is a screening tool designed to detect probable current psychiatric 
disorder in primary care settings; sensitivity (84%) and specificity (86%) are 
reasonable in the UK population (Goldberg et al, 1997). The threshold for ‘caseness’ 
on the GHQ-28 is a total score of 5 or more; by this criterion, over 11% of controls 
met threshold; this proportion was approximately doubled (21.2%) in participants 
with a history of a single episode of depression, and more than doubled again 
(47.1%) in those with a history of recurrent depression. Over half (52.1%) of those in 
the chronic/recurrent group screened positive on the GHQ-28. Overall, the high total 
GHQ-28 scores in the participants with a history of MDD emphasise the chronic 
nature of depression, and the long-term burden of depressive symptoms. 
 
In terms of both the individual sub-scales, and total GHQ-28 score, a gradient of 
abnormality (control < single episode MDD < recurrent MDD) was observed, with 
highly statistically significant differences between groups. Only the ‘severe 
depression’ subscale (GHQ D) significantly distinguished the chronic/recurrent 
group, who scored highest on this subscale. These results are consistent with the 
previous finding that patients with MDD, particularly those with a recurrent disorder, 
tend to have chronic depressive symptoms (Judd et al, 1998), as do patients with 
bipolar disorder (Judd et al, 2002), in which bipolar II disorder may have a more 




Partial correlations were conducted (controlling for age, gender and GHQ total Likert 
score) between the MDQ and other psychometric measures in the combined sample 
and subgroups. Results are detailed in Table 21. 
 
 MDQ total score 
Group combined control seMDD rMDD crMDD 
n 2942 2314 317 206 97 
 r p r p r p r p r p 
Age/onset     -.146 .009 -.176 .013 .009 .927 
Episodes       .095 .181   
           
EPQ N .257 <.001 .218 <.001 .238 <.001 .264 <.001 .030 .777 
EPQ E .054 .004 .069 .001 .089 .118 .050 .484 .095 .369 
           
LM-I -.061 .001 -.056 .008 -.014 .803 -.137 .054 -.036 .738 
LM-D -.052 .005 -.050 .017 -.025 .669 -.109 .126 .030 .782 
VF -.009 .612 -.036 .088 -.038 .513 .072 .311 .118 .269 
DS -.050 .008 -.050 .018 -.041 .473 -.085 .233 .135 .206 
MHV -.100 <.001 -.120 <.001 -.146 .010 -.055 .439 -.081 .451 
p <= .01 in bold; EPQ - Eysenck Personality Questionnaire - Revised (Short Form) 
N - Neuroticism; E - Extraversion; LM-I: logical memory immediate; 
LM-D: logical memory delayed; VF: verbal fluency; DS: digit symbol; 
MHV: Mill Hill Vocabulary 
Table 21 MDQ, personality and cognitive partial correlations 
 
If age of onset is on average 8 to 10 years lower in BP, compared to MDD, and total 
MDQ score is a valid dimensional measure of bipolarity, it would be expected to 
correlate negatively with age-of-onset, as it did in the combined patient group: 
r = -.191, p = 2 x 10-6, but also in the seMDD and rMDD subgroups. This may 
provide some convergent validity of a dimensional measure of bipolarity in patients 
with MDD, however some participants may have been ‘false unipolars’.  More 
rigorous phenotyping of mania to exclude those with bipolar II and bipolar NOS 
would be necessary to exclude this possibility.  
 
If MDQ indicated bipolarity in the rMDD sample, it might have been expected to 
correlate positively with number of depressive episodes (as in Chapter 2), but the 
small positive correlation seen here was not statistically significant. This may be 





Neuroticism and Extraversion 
The MDQ showed positive moderate-sized significant correlations with Eysenck’s 
neuroticism in the combined sample, and the seMDD and rMDD groups. There was 
no correlation with the crMDD group. Extraversion was very weakly correlated with 
the MDQ in the control group only.  
 
Cognition 
A meta-analysis of cognitive deficits in bipolar disorder showed a modest effect on 
general IQ, r = .05, but this persistent association appears to be mainly the result of 
deficits in performance, rather than verbal IQ (Goodwin & Jamison, 2007, 279). 
However it should be noted that this is an area of conflicting evidence, probably 
because of the different definitions of mood disorders used and the difficulties 
inherent in cognitive testing. One recent cohort study (MacCabe et al, 2010) used 
longitudinal data from over 900 000 individuals in Sweden to examine the 
relationship between scholastic achievement at age 16 and risk for BP in adulthood, 
controlling for potential confounders including socioeconomic group and parental 
education. They detected a U-shaped curve, with the highest achievers at greatest 
risk. 
 
The Mill Hill Vocabulary test (MHV) of verbal ability correlates highly with Raven’s 
progressive matrices, a performance test of general intelligence. In the current study 
there was a small negative, but highly significant correlation between the MDQ and 
MHV in the combined sample. Small negative effects were present but not 
statistically significant in the individual and combined patient groups. The largest 
effect was found in the control sample alone (r = -.120, p = 1 x 10-8). This subtle but 
highly significant effect may be evidence of an association between a tendency to 
experience manic symptoms and subtle impairment of general intelligence in the 
normal population. If this finding was replicated, it would provide external validation 
to support Kraepelinian assertion that there is no distinct border between normality 




Small negative correlations were seen with the other cognitive measures in most 
groups, however in general the effects were small and not statistically significant, 
except for Logical Memory-Immediate (uncorrected p = .008) in the control group. 
This result did not withstand correction for multiple testing. This serves to emphasise 
the subtle nature of cognitive impairment in mood disorders. 
 
Psychological Distress 
The GHQ total score provided an overall measure of current levels of psychological 
distress. To assess the predictive validity of the MDQ, a multiple regression analysis 
was conducted, using hierarchical, blockwise entry. Neuroticism correlates highly 
with psychological distress and was therefore entered into the model first. Dummy 
variables were created to allow the diagnostic groups (seMDD, rMDD and crMDD – 
seMDD was the baseline) to be entered, followed finally by the MDQ total score (see 
Table 22). 
 
 R2  B SE B β p 
Model 1 .210 Constant -0.071 0.375   
  EPQ-N 0.681 0.054 .458 <.001 
Model 2 .237 Constant -0.356 0.378   
  EPQ-N 0.591 0.056 .398 <.001 
  Group1 1.505 0.410 .141 <.001 
  Group2 2.167 0.545 .156 <.001 
Model 3  .242 Constant -0.564 0.391   
  EPQ-N 0.560 0.058 .377 <.001 
  Group1 1.455 0.410 .137 <.001 
  Group2 2.014 0.549 .145 <.001 
  MDQ 0.118 0.060 .075 .048 
p < .05 in bold 
Table 22 GHQ Total multiple regression model 
   
 
Using this model, the MDQ accounted for only 0.5% of the variance, compared with 
21% for the EPQ-N and 2.7% for the diagnostic group. Nevertheless this was a 
statistically significant result. This provides modest evidence of the predictive 






In this Chapter a dimensional measure of mania was examined in a large population-
based sample. 
 
The instrument showed very similar internal reliability as it did in a US population-
based study. Principal component analysis suggested a 3-factor internal structure, 
with ‘energised-activity’, ‘racing thoughts-irritability’ and ‘disinhibition/risk-taking’ 
components.  
 
Early age of onset, and recurrence (chronic/recurrent > recurrent > single) was 
associated with higher total MDQ score, suggesting that in MDD, manic symptoms 
are a marker of severity (Cassano et al, 2004). Non-euphoric manic symptoms 
(irritability, racing thoughts and distractibility) were the most commonly 
experienced, as in other studies (Serretti & Olgiati, 2005). In controls (n = 2252), 
number of historical manic symptoms, as measured by the MDQ, showed a highly 
significant ( p = 1 x 10-8) but modest negative correlation (r = -.120) with a measure 
of general intelligence, consistent with most findings in bipolar disorder. In 
participants with MDD, MDQ score showed a trend towards cognitive impairment. 
Taken together, these finding suggest a continuum of impairment, rather than a 
distinct boundary between ‘normal’ and abnormality, or between MDD and BP, and 
support Angst’s 2-dimensional model of affective disorder (Figure 5). 
 
In the early-onset sample (see Table 10), MDQ correlated with Cloninger’s Novelty 
Seeking (NS), but not Harm Avoidance (HA). In the population-based study, MDQ 
correlated with N but not E, as has been described (Bowen et al, 2011). Although E 
has been found to correlate with NS (r = .44), and N correlates with HA (r = .59) 
(Zuckerman & Cloninger, 1996), there is considerable unexplained variance, making 
it hard to compare these different personality dimensions. It appears that E and N do 




About half of those with more than one episode of MDD were current ‘cases’ of 
psychological distress by GHQ-28. This finding serves to emphasise the chronic 
burden of distress caused by these conditions. MDQ modestly predicted current 
levels of psychological distress, even after controlling for neuroticism and diagnostic 
group, indicating that it has divergent and predictive validity. 
 
Clinical Implications 
It appears that the use of a dimensional measure of mania has validity in patients 
with MDD. In patients who are at higher risk of BP, such as males, those with an 
early age of onset, or a recurrent or chronic depression, it may be clinically useful to 
rate manic symptoms as this could inform treatment choices, possibly away from 
antidepressants towards mood stabilisers. Classifying mood disorders on the basis of 
recurrence or chronicity, and including personality measures, rather than just polarity, 
may have more predictive validity (clinical utility). 
 
Strengths and Limitations 
The large sample size increased power to find small effects. Detailed cognitive 
phenotyping allowed analysis of MDQ associations in a population-based sample. 
Diagnostic assessment was not carried out by psychiatrists, but use of a structured 
instrument, and a continuous training program for researchers, produced reasonable 
inter-rater reliability. Drug treatment was a potential confounder but this information 
was not available at the time of analysis. Lack of a traditionally defined bipolar 
group limited the analysis, and more systematic assessment of hypomania would be 
necessary to  reduce the proportion of MDD participants who may have had 
unrecognised bipolar disorder.  Retrospective collection of age-of-onset and number 




Chapter 5: Conclusions 
 
The introduction of operationally defined categories in psychiatry led to more 
reliable diagnostic agreement and communication between clinicians and 
researchers, and more reliable comparison of groups and outcomes (Lawrie et al, 
2010). However, these categories are difficult to apply in mood disorder (Andreasen 
et al, 1981), of limited validity (Kendell & Jablensky, 2003) and arguably too narrow 
in bipolar disorder (Angst et al, 2010, 2011). Poor diagnostic validity hampers our 
understanding of the underlying structures and aetiologies of mood disorder 
(Kendell, 1982), and poor utility impairs patient care (Kendell, 1989). 
 
Although other clinical features can help differentiated mood disorders, current 
classification is dominated by the necessity to establish the presence or absence of a 
history of mania (Forty et al, 2008), whilst degree of recurrence has been discarded 
as a diagnostic criterion. Although full-blown manic episodes are easy to identify, 
most patients with mood disorder experience less extreme, but clinically significant 
symptoms (Judd & Akiskal, 2003), which are time-consuming to elicit reliably. 
Mania questionnaires such as the MDQ (Hirschfeld et al, 2000) may speed up 
assessment and improve diagnostic sensitivity, however the validity (Zimmerman et 
al, 2004) and utility of this approach, or novel diagnostic categories such as BSD 
(Ghaemi et al, 2002) are the subject of uncertainty. In the preceding chapters, three 
studies were conducted in an attempt to address some of these uncertainties.  
 
As was described (see page 6 and Table 2), methods to establish validity - based on 
finding external correlates outwith defining characteristics - were probably first 
formally proposed by Robins & Guze, and have since been elaborated by Kendler, 
and latterly Andreasen (Kendell & Jablensky, 2003). External validators may be 
considered as antecedent (e.g., familial, personality, genetic), concurrent (e.g., 






In Chapter 3, a genetic study of mood disorder, a replication of a previous finding 
(Thomson et al, 2004) was attempted. A polymorphism in the region (rs1202874) 
was associated with mood disorder, particularly BP, but the association was not 
found with the original markers. As in the previous study, a sub-sample of those with 
traditionally defined MDD were positive for Ghaemi’s criteria for bipolar spectrum 
disorder. When these cases were combined with the BP group the effect size, and 
statistical significance increased. It could be argued from this finding provides 
antecedent biological validity of the BSD category, and that these ‘unipolar’ patients 
should be re-classified as ‘bipolar’. However, the failure to replicate the association 
using the original markers made the result hard to interpret. Recent approaches to the 
elucidation of the genetics of mood disorder involve association studies using 
hundreds of thousands of genetic markers, and much larger sample sizes (Sklar et al, 
2011). Newer polygenetic approaches may be informative (Hamshere et al, 2011).   
 
Gender 
In Chapter 2, males with early onset MDD tended to score higher on dimensional 
measures of historical manic symptoms. Furthermore, in the larger population-based 
study, when there were gender differences in total MDQ score, males scored higher. 
As the female to male ratio in MDD is greater than one, but the gender ratio is equal 
to one in BP, this provided some antecedent validation of the MDQ. 
 
Clinical Course 
Modest but significant correlations were found between MDQ and HCL and number 
of episodes in the high-risk early-onset sample, and there was also a modest but 
highly significant negative correlation with age-of-onset and MDQ in the population-
based sample (r = -.191, p = 2 x 10-6).  The population-based MDD sample was 
separated into groups according to degree of recurrence. There is evidence that 
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bipolar disorder tends to be more recurrent than MDD, and a greater proportion of 
bipolar patients suffer a chronic/recurrent course, compared to those with MDD. 
MDQ scores showed a significant gradient across groups (crMDD > rMDD > 
seMDD), with ~30% of patients in the chronic recurrent group meeting threshold (≥ 
7) for a positive screen on the MDQ, some of whom could have been ‘false 
unipolars’. Overall, clinical course provided reasonable antecedent validation of the 
MDQ, and supported the assertion that manic symptoms in depression are markers of 
severity (Cassano et al, 2004). 
 
Familiality 
Systematic ascertainment of family history in the early-onset sample allowed 
comparison of the MDQ and HCL in probands with and without heavily ‘loaded’ 
pedigrees. Those with loaded pedigrees scored slightly higher on the MDQ but the 
difference was not statistically significant. This did not provide clear familial 
evidence of the validity of the MDQ, however the Generation Scotland cohort is a 
family study (Smith et al, 2012), and analysis of the heritability of the MDQ in this 
sample could provide familial validation. 
 
Personality 
The relationship between personality and affective disorders is complex: for 
example, personality traits may be conceived of as propensities that predispose 
individuals to affective disorders; as modifiers of affective states; as attenuated 
expressions of affective illness; or as orthogonal dimensions (Akiskal et al, 1983a). 
Furthermore some affective states, previously considered personality disorders, have 
been shown to respond favourably to pharmacological treatment (Silva de Lima et al, 
2005). Measurement of personality in affective disorders is potentially complicated 
by state effects (Hirschfeld et al, 1983; Morey et al, 2010), nevertheless these 
reservations do not negate the use of personality traits as endophenotypes (Savitz & 
Ramesar, 2006), and in this work I assessed the relationship between personality 
traits and the mood disorder questionnaire to determine its validity.  
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Neuroticism and Extraversion-Introversion 
The systematic assessment of personality remains a controversial area: no clear 
consensus has emerged as to the number or contents of the dimensions that should be 
used to describe personality (Matthews et al, 2003). However Eysenck’s Neuroticism 
(N) and Extraversion-Introversion (E) are probably the most widely studied 
(Eysenck, 1959, 1967). Previous studies which attempted to differentiate bipolar 
from unipolar subjects on N and E tended to be small and failed to control for 
affective state, but more recently, larger studies controlling for affective state (Smillie 
et al, 2009; Jylhä et al, 2010) have not been able to differentiate unipolar from 
bipolar patients on N and E. In the population-based study, Extraversion was higher 
in controls and in those with single episodes of depression than in those with 
recurrent or chronic/recurrent depression; Neuroticism showed a gradient across 
categories with N lowest in controls, and highest in the chronic/recurrent group. This 
indicates that N is a marker of severity and MDQ was modestly correlated with N, 
except perhaps surprisingly in the chronic/recurrent group. Overall, a lack of clear 
published differences between bipolar and unipolar disorder on N and E made these 
results difficult to interpret, and arguably prevented the drawing of conclusions on 
the validity of the MDQ based on these personality traits.  
 
Temperament and Character 
Personality can be conceived in terms of constitutional or genetic tendencies, 
referred to as ‘temperament’ and learned attributes acquired during childhood 
development, referred to as ‘character’. Cloninger’s Temperament and Character 
Inventory (Cloninger et al, 1993) and the TEMPS-A (Akiskal et al, 2005c) attempt to 
capture these dimensions and were measured in the early-onset sample. Previous 
research had shown associations between bipolar disorder and Novelty Seeking 
(Young et al, 1995; Evans et al, 2005); associations between bipolar disorder and 
Self Transcendence had been predicted (Cloninger et al, 1998); and compared to 
unipolars, bipolars have been found to score higher on measures of cyclothymic 
temperament (Di Florio et al, 2010). On these measures, in the early-onset sample, 
the MDQ showed moderate positive correlations of statistical significance which 
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persisted after controlling for affective state: this finding supported the validity of the 
MDQ (and HCL) as a measure of bipolarity in MDD. In mood disorders research, 
temperamental evaluation may be more useful in distinguishing mood disorders than 




Strong and highly significant correlations between the MDQ and the clinician-
administered HCL provided some evidence of criterion validity. This indicates that 
sub-clinical manic symptoms can be reliably elicited by clinical interview or 
questionnaire. Use of questionnaires may be an efficient way to increase diagnostic 
sensitivity to historical manic experiences (Forty et al, 2010). 
 
Convergent and divergent validity 
It has been found that euthymic patients with bipolar disorder have subtle 
impairments in general intelligence that have not been reliably detected in euthymic 
unipolar patients (Goodwin & Jamison, 2007). In the population-based sample a 
modest, but highly significant negative correlation was found between the MDQ and 
a measure of general intelligence, the Mill Hill Vocabulary test. This was also present 
to a slightly lesser extent in controls. This finding provides some evidence of the 
convergent validity of the MDQ in MDD, but it may also indicate that a history of 
manic symptoms is associated with subtle cognitive impairment in the ‘normal’ 
population. In the early-onset study, the absence of any correlation between the 
MDQ and either Cloninger’s Harm Avoidance, or anxious or depressive temperament 
provided some evidence of divergent validity. 
 
In the early-onset sample, reaction time findings were unexpected, and the results 
from the genetic study made them harder to interpret: cases were on average slower 
than controls, as would be expected, but the MDQ correlated negatively with 
 
89 
reaction time: i.e., high scorers on the MDQ reacted faster. Patients carrying the 
apparent bipolar risk C allele at rs1202875 (n = 9) reacted more slowly, however they 
also scored lower on the MDQ, HCL, cyclothymia and irritability scales which 
suggested they had fewer manic features. Given the very small numbers and lack of 
replication, the genetic results should probably be given less weight. Attempts could 
be made to replicate the unexpected negative correlation between MDQ and reaction 
time. The Generation Scotland cohort has reaction time data on around a thousand 
participants, and this could allow an attempt at replication. 
 
MDQ showed a modest but highly significant correlation with measures of general 
distress (GHQ-28). Multiple regression allowed diagnostic group and Eysenck’s N to 
be controlled. Over and above these factors, the MDQ total score explained 0.5% of 
the variance. This provided weak evidence of convergent and predictive validity. 
From a clinical perspective, predictive validity is the most important feature of a 
diagnostic entity (Kendell, 1989); the clinical utility of using the MDQ can be 




A principal component analysis in population-based sample allowed an exploration 
of the underlying structure of the MDQ, and comparison of its performance in 
Scotland, compared to other countries. As in other studies (Hirschfeld et al, 2003b), 
it was internally reliable, and most items loaded strongly onto a single ‘energised-
activity’ component, providing some evidence of construct validity. Two lesser 
factors, a ‘racing thoughts – irritability’ and a ‘disinhibited’ component were also 
detected, however the steep scree plots demonstrated that the first factor was 
dominant. 
 
Predictive Validity (Utility) 
Patients want to know how their illness is likely to progress, and clinicians need to 
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make decisions about what treatment to recommend: in clinical practice the most 
important aspect of the validity of a diagnostic concept is its predictive validity, also 
know as utility, or usefulness (Kendell & Jablensky, 2003). 
 
In Chapter 2, the early-onset depressed MDD patients were treated as usual and 
followed up for 3 months. MDQ and HCL showed weak but non-significant negative 
correlations with change in depressive symptoms. It has been recognised that, in 
general, bipolar patients are more likely than unipolars to suffer adverse effects from 
antidepressant treatment. Three-quarters of the patients (n = 36) were receiving 
unopposed antidepressant treatment at follow up – in these individuals there was 
moderate and significant positive correlation between MDQ, restlessness and 
suicidal thoughts. This provided some evidence of predictive validity. If this finding 
was replicated, it could indicate that those with early-onset MDD who also score 
highly on the MDQ, may need particularly careful monitoring for suicidality. A more 
speculative implication is that, as in bipolar depression (Sidor & Macqueen, 2011), 
unopposed antidepressant therapy may not be the best first-line drug treatment for 
this group . 
 
Summary 
The validity of the MDQ was examined in an early-onset and population-based 
sample with MDD, and in a large group of controls. On clinical, psychological and 
cognitive measures the MDQ showed modest or moderate antecedent and concurrent 
validity. Findings supported a spectrum of severity, with no clear boundaries between 
‘normality’ and MDD or BP. A genetic association study (MacIntyre et al, 2010) 
provided some evidence that Ghaemi’s criteria for BSD may identify individuals 
more appropriately considered bipolar. In the early-onset MDD sample, the MDQ did 
not predict recovery but, in those on antidepressants, it correlated with subjective 





Clinical implications that may be drawn from this research are threefold. In those 
with MDD (particularly those with other risk factors for BP such as early age of 
onset and a recurrent disorder) it may be useful to rate manic symptoms to (1) 
identify those who may require more intensive monitoring of suicidality, (2) inform 
treatment decisions, possibly away from antidepressant towards mood stabilisers.  
Thirdly, classifying mood disorders on the basis of prior course, and including 
personality measures, along with polarity, may have more clinical utility. 
 
Further research 
The longstanding tension between categorical and dimensional classification will 
perhaps never be resolved, however a pragmatic approach combining both may be 
useful. Novel diagnostic criteria, and probabilistic approaches (Mitchell et al, 2008) 
should have their utility firmly established by follow up studies before their use is 
widely promoted. The predictive validity of the MDQ should be assessed by follow-
up studies of the Generation Scotland cohort, using record linkage and re-contacting 
of participants, preferably along with drug treatment data. 
 
A randomised clinical trial in early-onset MDD, comparing antidepressant 
monotherapy with a treatments usually reserved for bipolar depression may be 
justified. 
 
Creating rational treatments for mood disorders is likely to depend on understanding 
their aetiology, and this may rests on carefully phenotyping of patients. As larger 
population based-samples become available, the use of dimensional measures may 
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Appendix 1 Log transformed TCI/HA correlations 
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Appendix 2 Partial TEMPS-A correlations 
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